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I. ABSTRACT 
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal 
malignancies worldwide. More than 50% of patients are diagnosed with late-stage 
disease. Exosomes are a group of extracellular vesicles released by different types of 
cells, containing proteins, nucleic acids and lipids, mediating intercellular 
communication, and thus affecting physiological and pathological conditions. Tumor-
derived exosomes have been shown to induce a pre-metastatic niche in the target organ 
to promote metastasis. 
Methods: We isolated exosomes from cell culture supernatants of a highly metastatic 
pancreatic cell line L3.6pl and a PDAC patient derived primary cell line TBO368 by 
ultracentrifugation. Exosomes were characterized by Western blotting, nanoparticle 
tracking analysis and transmission electron microscopy. The protein content of 
exosomes was analyzed by mass spectrometry. The potential effects of pancreatic 
cancer-derived exosomes on NK cells were investigated by immunofluorescence and 
flow cytometry. The exosomal TGF-β1 levels in serum of patients with PDAC were 
quantified by ELISA.  
Results: We found that adhesion receptors, especially integrins such as integrin αv and 
integrin β5, which are associated with liver-specific metastases, were enriched in 
pancreatic cancer-derived exosomes. These exosomes also displayed a variety of 
immune regulatory factors, such as TGF-β1, Nectin-2 and PVR. Then we co-cultured 
NK cells with exosomes derived from pancreatic cancer cells. After co-culture, the 
expression of NKG2D, CD107a, TNF-α and INF-γ in NK cells was significantly 
downregulated. NK cells also exhibited the decreased level of CD71 and CD98, as well 
as impaired glucose uptake ability. In addition, NK cell cytotoxicity against pancreatic 
cancer stem cells was attenuated. Moreover, pancreatic cancer-derived exosomes 
induced the phosphorylation of Smad2/3 in NK cells. Compared to healthy donors, 
serum exosomal TGF-β1 was significantly increased in patients with PDAC.  
2 
 
Conclusion: In this study, we show that tumor-derived exosomes are responsible for 
pre-metastatic niche formation in the liver of PDAC. The inhibitory effects of 
pancreatic cancer-derived exosomes on NK cells represent a mechanism allowing 
metastatic tumor cells to escape from NK cell immune surveillance in the pre-metastatic 
niche. We also demonstrate that serum exosomal TGF-β1 was significantly increased 
in patients with PDAC. In conclusion, these findings emphasize the 
immunosuppressive role of pancreatic cancer-derived exosomes and provide new 
insights into our understanding of NK cell dysfunction in the pre-metastatic niche 
formation of PDAC. 
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II. INTRODUCTION  
2.1. Pancreatic cancer 
2.1.1. Background  
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies 
worldwide[1]. The majority of patients with pancreatic cancer are diagnosed at an 
advanced stage and lose the opportunity for curative surgery[2]. Even after R0 resection 
followed by adjuvant chemotherapy and/or radiotherapy, most patients will eventually 
have recurrence[3-5]. The Surveillance, Epidemiology and End Results (SEER) 
Program (https://seer.cancer.gov/statfacts/) reveals that the 5-year overall survival for 
patients with localized disease is 34.3% between 2008 and 2014 in the United States. 
For those who present with distant metastases, this drops to merely 2.7%. These 
daunting statistics indicate that of importance is improving our understanding of the 
metastatic process to reduce the incidence of metastasis and develop effective 
therapeutic strategies for PDAC patients. 
2.1.2. Metastasis of pancreatic cancer 
In 1889, Stephen Paget firstly proposed that the interplay between tumor cells (the 
‘seeds’) and the target organ microenvironment (the ‘soil’) promoted organ-specific 
metastasis formation in breast cancer[6]. From then on, the underlying mechanisms of 
metastasis have been investigated and discussed for more than one century. Over the 
past few decades, researchers have shed light on the cellular and molecular events 
during the process of metastasis.  
As an important hallmark of cancer, metastasis is a complex process that propagates 
tumor cells from the site of origin to distant tissues, also known as the metastatic 
cascade[7-10]. The metastatic process in PDAC involves the detachment of pancreatic 
cancer cells from the primary tumor, their intravasation into the bloodstream, their 
extravasation and entry in the pre-metastatic niche, as well as their survival and 
colonization to form macroscopic metastases at distant sites[11]. The most common 
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frequent distant metastatic sites for PDAC include liver, lung and brain[12]. 
Considered as precursors of metastasis, circulating tumor cells (CTCs) represent tumor 
cells that are shed from the primary tumor and enter the bloodstream[13]. Rapid 
technological advances have enabled detection and isolation of CTCs from peripheral 
blood across a variety of cancer types, including breast, lung, colorectal and pancreatic 
cancer[14-17]. Birte Kulemann et al. reported that CTCs were detected in 67.3% of 
patients with PDAC (39/58)[18]. Theoretically, CTCs may reach any organ and tissue 
by circulation. Actually, most of CTCs within the bloodstream will die due to loss of 
matrix-derived survival signals and hemodynamic shear stress[19, 20]. Therefore, one 
key step for metastatic cascade is the capability of CTCs to survive and colonize in the 
new microenvironment of the target organ. It has been well recognized that tumor 
growth and progression are dependent on the tumor microenvironment. On the contrary, 
little is known about the dynamic microenvironment of the target organ for metastasis 
in PDAC. 
2.1.3. The hepatic pre-metastatic niche in pancreatic cancer 
The term “premetastatic niche” describes the microenvironment in a secondary organ 
that has been affected by the primary tumor to support tumor growth in advance of 
tumor cell entry[21]. Many studies have identified the existence of pre-metastatic 
niches in different organs, such as lymph nodes, lung, liver, bone and brain[22-26]. Liu 
Y et al. summarized six characteristics of the pre-metastatic niche, including 
immunosuppression, inflammation, lymphangiogenesis, angiogenesis/vascular 
permeability, organotropism, and reprogramming[27]. The hepatic pre-metastatic niche 
has been revealed in orthotopic PDAC mouse models[28]. However, the underlying 
mechanisms of liver pre-metastatic niche formation are still not fully understood in 
human PDAC. 
Metastatic pancreatic cancer cells that enter the liver have to encounter a totally new 
microenvironment, including different cells and extracellular matrix (ECM). 
Hepatocytes occupy about 80% of all cells in the liver. Other non-parenchymal cells in 
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the liver consist of sinusoidal endothelial cells, hepatic stellate cells (HSCs), Kupffer 
cells (KCs), and lymphocytes[29]. During the process of tumor initiation and 
progression, phenotype and functions of these cells are strongly influenced by the 
primary tumor. Among these cells, HSCs are the main driver for liver fibrosis[30]. 
Upon activation, HSCs are able to transdifferentiate into highly proliferative 
myofibroblasts. Increased production of growth factors and ECM by myofibroblasts 
triggers a fibrotic response, enhancing the survival and growth of metastatic tumor 
cells[31]. It has been revealed that liver metastases in PDAC-bearing mice were 
infiltrated and surrounded by abundant myofibroblasts[32]. KCs constitute 
approximately 10% of all liver cells. As resident macrophages in the liver, KCs have 
the phagocytotic activity and can kill tumor cells through the secretion of cytotoxic 
molecules, such as tumor necrosis factor (TNF)-α and reactive oxygen species 
(ROS)[33]. However, under certain conditions, KCs can also produce and secret pro-
tumorigenic factors, including hepatocyte growth factors (HGF), vascular endothelial 
growth factors (VEGF), and matrix metalloproteinases (MMP). These cytokines and 
growth factors can facilitate tumor cell invasion into the parenchymal space, promote 
tumor cell proliferation and enhance angiogenesis[34]. Therefore, HSCs and KCs are 
postulated as two candidates involved in the liver pre-metastatic niche formation[35]. 
Recently, Jae W. Lee et al. reported the activation of signal transducer and activator of 
transcription 3 (STAT3) signaling and upregulation of serum amyloid A1 and A2 in 
hepatocytes during early pancreatic tumorigenesis in mouse models. Thereby, 
hepatocytes were able to induce the accumulation of myeloid cells and fibrosis in the 
liver, which ultimately favored the survival and colonization of metastatic tumor 
cells[36]. In addition, intrahepatic lymphocytes and bone marrow-derived cells 
(BMDCs) also participate in liver pre-metastatic niche formation of PDAC[31]. 
6 
 
Figure 1. The hepatic pre-metastatic niche in PDAC. Under the influence of the 
primary tumor, hepatocytes, sinusoidal endothelial cells, hepatic stellate cells (HSCs), 
Kupffer cells (KCs), lymphocytes and bone marrow-derived cells are involved in liver 
pre-metastatic niche formation of PDAC. 
2.1.4. Cancer immunoediting in the pre-metastatic niche  
The human liver is often perceived as a digestive organ, which are responsible for bile 
production, nutrients storage, synthesis of plasma proteins and detoxification. In fact, 
the liver also has a large amount of immune cells, including myeloid cells and lymphoid 
cells[37]. The immune cells in the liver serve as a barrier against metastatic tumor cells. 
However, the primary tumor can undermine the immune response in the pre-metastatic 
niche, which ultimately leads to the immune escape of metastatic tumor cells. The 
concept of cancer immunoediting to explain the dynamics of immune responses in 
tumor progression is widely accepted in the field of cancer immunology. Cancer 
immunoediting, both pro-tumorigenic and anti-tumorigenic, is composed of three 
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processes: elimination, equilibrium and escape[38-40]. Recent advances have begun to 
uncover the role cancer immunoediting in pre-metastatic niche formation.  
In the elimination process, both innate and adaptive immune cells are responsible for 
cancer immunosurveillance[41]. However, during pancreatic cancer initiation, 
malignant cells upregulate natural killer cell activating receptor ligands and 
downregulate inhibitory ligands. For example, major histocompatibility complex class 
I-related chain A and B (MICA/B) are frequently overexpressed on the surface of 
pancreatic cancer cells. Such ligands bind to NKG2D receptor to activate natural killer 
(NK) cells, triggering NK cell cytotoxicity and leading to the secretion of pro-
inflammatory cytokines, which regulate other immune cells and facilitate their anti-
tumor immune response[42]. In addition, CD8+ T cells can recognize and eliminate 
pancreatic cancer cells expressing tumor-associated antigens[43]. Therefore, in the 
elimination process, metastatic pancreatic cancer cells fail to colonize in the pre-
metastatic niche. 
In the equilibrium process, the immune cell in the liver and pancreatic cancer cells that 
have survived the elimination process enter into a dynamic equilibrium[44]. Pancreatic 
cancer stem cells (CSCs) are implicated in metastasis[45]. The quiescent behavior and 
longevity of pancreatic CSCs makes it easy to accumulate genetic and epigenetic 
alterations and survive in the equilibrium process[46]. Upon asymmetric division, a 
metastatic cancer stem cell generates a daughter stem cell for self-renewal and a 
daughter cell that undergoes further differentiation. The differentiated pancreatic cancer 
cells are subjected to immunosurveillance and most of them will be detected and 
destroyed by the immune cells. By contrast, poorly immunogenic tumor cells are more 
likely to escape from immune surveillance. In addition, the dependence of pancreatic 
CSCs on their niche also restrain their rapid proliferation[47]. The equilibrium process 
is functionally similar to the state of tumor dormancy[48]. The tumor cells may stay 
dormant in the liver for a long time before eventually becoming clinically apparent. 
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In the escape process, pancreatic cancer cells successfully evade immune destruction. 
The primary tumor is able to remodel the tumor microenvironment via secretion of 
immunosuppressive factors and recruitment of immunosuppressive cells, such as 
regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), both of 
which can attenuate the cytotoxicity of CD8+ T cells and NK cells[49-51]. Besides, 
during tumor progression, HSCs and KCs also promote immunosuppression in the liver. 
The immunosuppressive microenvironment in the pre-metastatic niche allows 
pancreatic cancer cells to rapidly proliferate. Finally, metastatic pancreatic cells and 
their differentiated progeny progressively grow into a visible metastasis in the liver. 
Taken together, the mechanisms by which the primary tumor affects the process of 
cancer immunoediting may explain the immune escape of tumor cells in the hepatic 
pre-metastatic niche of PDAC. 
2.2. Natural killer cells 
2.2.1. Background 
Natural killer (NK) cells are a group of innate lymphocytes, which are able to recognize 
and eliminate virus-infected cells and malignant cells. In addition to cytotoxicity, NK 
cells also secrete numerous cytokines and chemokines to influence the immune 
system[52]. Several activating and inhibitory receptors regulating NK cell function 
have been identified (Table 1)[53]. Among these receptors, NKG2D is one of the best 
characterized activating receptors. It is a type II transmembrane protein with a C-type 
lectin-like extracellular domain expressed on the surface of NK cells[54]. NKG2D can 
recognize and bind a diverse array of ligands. Among them, MICA, MICB, ULBP-4 
and ULBP-5 are transmembrane-anchored proteins, whereas ULBP-1, ULBP-2, 
ULBP-3 and ULBP-6 are glycophosphatidylinositol–anchored proteins[55]. Upon 
receptor-ligand interaction, NKG2D phosphorylates DAP10 or DAP12, recruits and 
activates phosphatidylinositol 3 kinase, thus triggering NK cell cytotoxicity[52].  
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Table 1. Activating/inhibitory receptors of NK cells and their ligands 
Activating 
receptors 
Ligands Inhibitory 
receptors 
Ligands 
NKG2C HLA-E CD96 NECTIN2 
NKG2D MICA  PVR 
MICB TIGIT NECTIN2 
ULBP1-6  PVR 
NKp46 Heparan sulfates PVRIG NECTIN2 
VIM  PVR 
Viral HA PD-1 PD-L1 
NKp44 Heparan sulfates  PD-L2 
KMT2E LAG3 MHC Class II 
PCNA NKG2A HLA-E 
Viral HA   
NKp30 BAG6   
 Heparan sulfates   
NCR3LG1   
 
2.2.2. NK cells and tumor 
NK cells have the capability to detect and kill tumor cells independent of antigen 
recognition, which is different from CD8+ T cells[56]. There are two manners for NK 
cells to eliminate cells. On the one hand, special ligands on the surface of tumor cells 
can bind to activating receptors on NK cells, which ultimately activates NK cell 
cytotoxicity[57]. On the other hand, the Fc portion of immunoglobulins on antibody-
coated tumor cells can bind to the FcγRIII on NK cells, leading to antibody-dependent 
cellular cytotoxicity (ADCC)[58]. In addition, NK cells can connect innate and adaptive 
immune system through secretion of immunomodulatory cytokines. Recently, NK cells 
are reported to harbor properties of adaptive immunity and abilities to maintain 
immunological memory[59].  
The role of NK cells in PDAC has received less attention but is increasingly being 
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recognized. Gürlevik E et al. reported that after primary tumor resection, gemcitabine 
treatment triggered NK cell cytotoxicity against tumor cells and decreased local 
recurrence incidence in orthotopic PDAC mouse models[60]. Ames E et al. found that 
NK cells preferentially killed pancreatic CSCs in vitro and intratumoral injection of NK 
cells in the human pancreatic cancer-bearing NSG mice reduced the percentage of 
pancreatic CSCs and tumor burden [61]. Therefore, immunotherapies based on NK 
cells are attracting more attention in PDAC. 
However, the ability to escape from immune surveillance has been established as a 
hallmark of tumor cells[10]. Increasing studies have revealed NK cells exhaustion in 
tumor[62]. NK cells in cancer patients produced decreased cytokines, downregulated 
activating receptors, as well as exhibited impaired cytolytic activity[63-65]. In addition, 
dysregulated cellular metabolism has been observed in dysfunctional NK cells[66]. 
Cong J et al. found that in lung cancer mouse models, the expression of 
gluconeogenesis enzyme fructose bisphosphatase 1 (FBP1) was upregulated in tumor-
infiltrating NK cells, which mediates dysfunction of NK cells by impairing 
glycolysis[67]. The mechanisms for NK cell dysfunction include direct inhibition via 
cell–cell contact, and indirect inhibition, via the production of inhibitory factors, such 
as TGF-β1, IL-10, PGE2 and IDO[68, 69]. 
2.2.3. NK cells in the pre-metastatic niche  
NK cells also play a non-negligible role in the control of metastasis[70]. In solid tumors, 
impaired NK cell function was associated with the incidence to develop metastases[71]. 
NK cells occupy about 5%-15% of lymphocytes in the peripheral blood. By contrast, 
in the liver, NK cells constitute around 30%-40% of intrahepatic lymphocytes[72]. 
During the metastatic process, when the metastatic pancreatic cancer cells enter the 
liver, their survival is largely dependent on their successful escape from NK cell 
immunosurveillance. Recent studies have identified the existence of an 
immunosuppressive microenvironment in the pre-metastatic niche[27]. However, the 
dynamics of NK cell in the hepatic pre-metastatic niche of PDAC still remains unknown. 
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2.3. Exosomes 
2.3.1. Background 
Cells can secrete different types of extracellular vesicles (EVs) to communicate with 
neighboring and distant cells[73]. In general, EVs can be classified as microvesicles 
and exosomes based on their size, as well as their mechanisms of biogenesis and release. 
Microvesicles, 100 to 1,000 nm in diameter, are generated by budding at the plasma 
membrane. By contrast, ranging from 30 to 100 nm in diameter, exosomes are formed 
after fusion of multivesicular endosomes/multivesicular bodies with the cell 
membrane[73, 74]. Through the transfer of various cargos, including proteins, nucleic 
acids (DNA, mRNA, microRNA, etc.) and lipids, exosomes can mediate intercellular 
communication, and thus affect physiological conditions[75, 76]. Moreover, exosomes 
are linked to a variety of diseases, including neurodegenerative diseases, disorders of 
the immune system, cardiovascular diseases and cancer[77-80]. 
 
Figure 2. Molecular composition of exosomes. Exosomes are composed of a lipid 
bilayer loaded with proteins, nucleic acids (DNA, microRNAs, mRNA) and lipids. As 
a mediator, exosomes can transfer signals and information to neighboring and distant 
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sites. CD9, CD63, CD81 are tetraspanin proteins in exosomes and often regarded as 
exosomal markers. 
2.3.2. Exosomes in pancreatic cancer 
Exosomes exist in various body fluids, such as serum, breast milk and saliva[81-83]. 
Recently, they have become potential non-invasive biomarkers in early diagnosis as 
well as prediction of treatment effect and prognosis in cancer patients. For example, 
Melo SA et al. reported that serum glypican-1 positive exosomes could be developed 
to distinguish patients with PDAC from healthy individuals and patients with benign 
pancreatic diseases. Levels of glypican-1 positive exosomes in serum correlated with 
tumor burden and the survival of PDAC patients[84]. Allenson K et al. found that 
compared to circulating cell-free DNA, patients with localized PDAC exhibit a higher 
percentage of detectable KRAS mutations in serum exosomes. This finding indicated 
that circulating exosomal KRAS mutation might be developed as a screen tool for early 
detection of PDAC.[85].  
In addition, as lipid bilayer membrane vesicles, exosomes are one ideal carrier for drug 
delivery in cancer treatment[86]. Kamerkar S et al. modified exosomes released by 
fibroblast-like mesenchymal cells to deliver short interfering RNA specific to KRAS 
mutation. Treatment of these engineered exosomes suppressed tumor growth in PDAC-
bearing mice and significantly increased their overall survival[87].  
In general, tumor cells are thought to synthesize more proteins, nucleic acids and 
lipids[88]. Exosomes secretion has been proposed as a mechanism to maintain cellular 
homeostasis by removing excess molecules from tumor cells[89]. Consequently, 
tumor-derived exosomes containing these cargos can be taken up by neighboring cells, 
as well as enter the bloodstream and travel to distant sites. Desmoplasia is a common 
feature for the tumor microenvironment of PDAC, which consists of pancreatic cancer 
cells, cancer associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), 
pancreatic stellate cells (PSCs), endothelial cells and various types of immune cells, as 
well as the extracellular matrix (ECM) that are produced by these cells[90]. The 
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interactions between the tumor cells and the tumor microenvironment are crucial for 
tumor initiation and progression. Tumor-derived exosomes have the capability to 
modulate the stromal cells to establish a favorable microenvironment that supports 
tumor growth. Masamune A et al. found that exosomes derived from pancreatic cancer 
cells induced the activation of PSCs[91]. Activated PSCs secreted a large amount of 
growth factors, chemokines, and ECM constituents to facilitate tumor growth and 
invasion[92]. Tumor growth is also dependent greatly on angiogenesis to supply 
nutrients and oxygen[93]. Zeng Z et al. reported that exosomes released from pancreatic 
cancer cells regulated gene expression in human umbilical vein endothelial cells 
(HUVECs) and induced angiogenesis in vitro[94]. Taken together, tumor-derived 
exosomes mediate intercellular communication within the tumor microenvironment of 
PDAC. 
2.3.3. The role of exosomes in pre-metastatic niche formation 
Tumor-derived exosomes can be released into the circulation and transferred to distant 
sites. Recent research has shed light on the role of tumor-derived exosomes in pre-
metastatic niche formation. For instance, exosomes released by colorectal cancer (CRC) 
cells could increase vascular permeability and promote liver and lung metastasis 
formation in mouse models[95]. In murine models of lung cancer and melanoma, 
tumor-derived exosomes delivered signals to lung epithelial cells and activated Toll-
like receptor 3 (TLR3), which elicited chemokine production and promoted neutrophil 
infiltration[96]. PDAC-derived exosomes recruited macrophages and neutrophils to the 
liver, and stimulated HSCs to synthesize fibronectin to promote liver metastasis[97]. In 
addition, exosomal integrins could determine organotropic metastasis[98]. In 
conclusion, tumor-derived exosomes are involved in pre-metastatic niche formation, 
including angiogenesis, immunosuppression and organotropism. 
2.4. Summary for this part 
In this study, we have investigated the effect of tumor-derived exosomes on NK cells 
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in pancreatic cancer. Here, we provide evidence that pancreatic cancer-derived 
exosomes carry abundant immunosuppressive factors and inhibit NK cell function, 
which contributes to pre-metastatic niche formation. 
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III. MATERIALS AND METHODS 
3.1.Materials  
3.1.1. Cell lines 
3.1.1.1.Human pancreatic cancer cell line L3.6pl 
L3.6pl is a highly metastatic human pancreatic cancer cell line variant originally 
derived from fast-growing variant (FG) of COLO375 after several cycles of in vivo 
selection. In orthotopic xenograft mouse models, L3.6pl cells exhibit an aggressive 
tumor growth with multiple spontaneous lymph node metastases and liver 
metastases[99]. 
3.1.1.2.Human pancreatic cancer cell line TBO368 
TBO368 was isolated from the primary tumor of a patient with PDAC from the 
Department of General, Visceral and Cancer Surgery, University Hospital of Cologne. 
The study has been approved by the Ethics Committee of the University of Cologne 
(BIOMASOTA (Biologische Material Sammlung zur Optimierung Therapeutischer 
Ansätze), ID: 13-091, approval in May 2016). To avoid the contamination of fibroblasts 
and immune cells, differential trypsinization was conducted until a homogenous 
population of EpCAM-expressing human pancreatic cancer cells was achieved by flow 
cytometry. In addition, we injected TBO368 cells subcutaneously into 6 to 8 week-old 
female NSG mice to verify their in vivo tumorigenicity. TBO368 cells were expanded 
and stored within 20 passages for future experiments.  
3.1.1.3.Mouse pancreatic cancer cell line Panc02 
Pan02 cells were developed from C57BL/6 mice treated with 3-methyl-cholanthrene. 
Pan02 cells are resistant to many standard chemotherapy applied in patients with 
PDAC[100]. Both orthotopic and intrasplenic injection of Panc02 cells resulted in 
multiple liver metastases in C57BL/6 mice[101]. 
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3.1.1.4.Human natural killer cell line NK-92 
NK-92 is a natural killer cell line isolated from the peripheral blood of a 50-year old 
patient with rapidly progressive non-Hodgkin's lymphoma[102]. The growth of NK-92 
cells is dependent on the presence of interleukin-2 (IL-2). NK-92 cells are cytotoxic to 
a wide range of human tumor cells, including pancreatic cancer cells[103].  
3.1.2 Materials for cell culture 
DMEM low Glucose Cat# 12320032, Gibco Invitrogen, Germany 
DMEM high Glucose Cat# 41965062, Gibco Invitrogen, Germany 
DMEM/F12  Cat# 31331093, Gibco Invitrogen, Germany 
Advanced DMEM/F-12 Cat# 12634028, Gibco Invitrogen, Germany 
RPMI 1640 + Glutamax-1  Cat# 61870044, Gibco Invitrogen, Germany 
MEM α, no nucleosides Cat# 22561021, Gibco Invitrogen, Germany 
Fetal bovine serum (FBS) Cat#FBS12-A, Capricorn Scientific GmbH, 
Germany 
Horse serum Cat# 16050122, Gibco Invitrogen, Germany 
Fetal Bovine Serum, exosome-depleted Cat# A2720803, Gibco Invitrogen, Germany 
DPBS  Cat# P04-36500, PAN Biotech, Germany 
Penicillin/Streptomycin (10,000 Units 
Penicillin/mL, 10 mg 
Streptomycin/mL) 
Cat# 15140122, Gibco Invitrogen, Germany 
 
Trypsin 0.05%/EDTA 0.02 % in PBS 
without Ca2+ and Mg2+ 
Cat# 25300054, Gibco Invitrogen, Germany  
EGF (Recombinant human EGF)  Cat# AF-100-15, PeproTech, UK 
bFGF (Recombinant human basic 
FGF)  
Cat# 100-18B-250, PeproTech, UK 
Insulin solution (human)  Cat# I9278, Merck, Germany 
B27 (B-27™ Plus Supplement (50X)) Cat# A3582801, Gibco Invitrogen, Germany  
rhIL-2 (Recombinant Human IL-2) Cat# 200-02, Peprotech, USA 
MEM vitamin mixture  Cat# 11120052, Gibco Invitrogen, Germany 
MEM Non-Essential Amino Acids 
(NEAA)  
Cat# 11140035, Gibco Invitrogen, Germany 
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L-Glutamine 200 mM (100X) Cat# 25030123, Gibco Invitrogen, Germany 
Normocin Cat# ant-nr-2, InvivoGen, San Diego, USA 
Trypan blue stain (0.4%)  Cat# T10282, Invitrogen, Germany 
DMSO  Cat#, A36720100, AppliChem, Germany 
PKH67 Cat# MINI67-1KT, Merck, Germany 
3.1.3 Medium for cell culture and cryopreservation  
3.1.3.1 Cell culture medium for pancreatic cancer cell lines 
Cell line Medium Supplements 
L3.6pl DMEM low            
 
10% FBS 
1% MEM vitamin mixture 
1% MEM NEAA 
2 mM L-Glutamine 
100 IU/mL Penicillin 
100 μg/mL Streptomycin 
TBO368 Advanced DMEM/F-12  10% FBS 
2 mM L-Glutamine 
100 IU/mL Penicillin 
100 μg/mL Streptomycin 
Panc02 RPMI 1640 + Glutamax-1 10% FBS 
100 IU/mL Penicillin 
100 μg/mL Streptomycin 
3.1.3.2 Cell culture medium for natural killer cell line 
Cell line Medium Supplements 
NK-92  
 
MEM α, no nucleosides  12.5% FBS 
12.5% Horse serum 
100 IU/mL Penicillin 
100 μg/mL Streptomycin 
0.02 mM Folic acid 
0.1 mM 2-mercaptoethanol 
0.2 mM Myo-inositol 
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2 mM L-Glutamine 
100 IU/mL rhIL-2 
3.1.3.3 Medium for tumor sphere formation assay  
Tumor spheres DMEM/F12            
 
20 ng/mL EGF 
20 ng/mL bFGF 
5 μg/mL insulin 
1X B27 
3.1.3.4 Cryopreservation medium 
90% FBS+10% DMSO  
3.1.4 Materials for exosomes isolation 
3.1.4.1 Exosomes isolation from cell culture supernatants 
Polycarbonate Bottle with Cap 
Assembly 
Cat# 355603, Beckman Coulter, USA 
3.1.4.2 Exosomes isolation from serum 
ExoQuick Exosome Precipitation 
Solution for Serum 
Cat# EXOQ5A-1-SBI, System Biosciences, 
Germany 
3.1.5 Real-Time Quantitative PCR 
3.1.5.1 Materials for Real-Time Quantitative PCR 
RNeasy Mini Kit Cat# 74106, QIAGEN, Germany 
High-Capacity cDNA Reverse 
Transcription Kit 
Cat# 4368814, Applied Biosystems, USA 
Fast SYBR™ Green Master Mix Cat# 4385612, Applied Biosystems, USA 
MicroAmp™ Optical 96-Well 
Reaction Plate 
Cat# N8010560, Applied Biosystems, USA 
MicroAmp™ Clear Adhesive Film Cat# 4306311, Applied Biosystems, USA 
3.1.5.2 Primer sequences used for PCR 
 5’-3’ 
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hKras exon2 seq-for TGAAGTACAGTTCATTACGATACACG 
hKras exon2 seq-rev GGAAAGTAAAGTTCCCATATTAATGGT 
MICA-for CTGTGCCCTCTGGGAAAGTG 
MICA-rev CGTCCCAACTGGGTGTTGAT 
MICB-for CCTGTGCCCTCTGGGAAG 
MICB-rev GTGGTCTCCTGTCCCAACTG 
ULBP1-for TGGCAGATGAGGAGAGTTGTTTA 
ULBP1-rev TGTTGAGCCGACAATGTCCT 
ULBP2-for AAGTGCAGGAGCACCACTC 
ULBP2-rev TGCTCACAGGAGCCTTTTGG 
ULBP3-for AAGAGCTGGCTTAGGGACTTC 
ULBP3-rev TATCACCTTCCACCTGTCACTC 
3.1.6 Materials for Western blot (WB) 
3.1.6.1 Reagents and Consumables for Western blot 
cOmplete™ Lysis-M Cat# 4719956001, Merck, Germany 
cOmplete™ ULTRA Tablets, Mini, 
EASYpack Protease Inhibitor Cocktail 
Cat# 5892970001, Merck, Germany 
PhosSTOP™ Cat# 4906845001, Merck, Germany 
Pierce™ BCA Protein Assay Kit Cat# 23225, Thermo Scientific™, Germany 
Pierce™ LDS Sample Buffer, Non-
Reducing (4X) 
Cat# 84788, Thermo Scientific™, Germany 
Roti®-Block, 10X Cat# A151,2, Carl Roth, Germany 
SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate 
Cat# 34577, Thermo Scientific, Germany 
Western Blotting Filter Paper, Extra 
Thick, 8.5 cm x 9 cm 
Cat# 88610, Thermo Scientific, Germany 
PVDF membrane 0.2µM Cat# 741260, MACHEREY-NAGEL, 
Germany 
PageRuler™ Prestained Protein 
Ladder 10 to 180 kDa 
Cat# 26617, Thermo Scientific, Germany 
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3.1.6.2 Buffer systems for Western blot 
Running buffer (Tris-Glycine/SDS), pH 8.3 
25 mM Tris  
190 mM Glycine  
0.1% SDS  
ddH2O  
Transfer buffer, pH 8.3 
25 mM Tris  
190 mM Glycine  
20% Methanol  
ddH2O  
Washing buffer (TBST) 
20 mM Tris  
150 mM Sodium Chloride  
0.1% Tween-20  
ddH2O  
Adjust pH to 7.4–7.6 with HCl  
Antibody dilution solution 
1X Roti-Block in H2O  
3.1.6.3 Antibodies for Western blot 
Antibody  Company  Catalog Specificity Host 
CD9 System 
Biosciences 
EXOAB-KIT-1-SBI human rabbit 
CD63 System 
Biosciences 
EXOAB-KIT-1-SBI human rabbit 
CD81 System 
Biosciences 
EXOAB-KIT-1-SBI human rabbit 
Alix Santa Cruz sc-53540 human mouse 
TSG101 Santa Cruz sc-136111 human mouse 
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Flotillin-1 Santa Cruz sc-74566 human mouse 
Rab5 Santa Cruz sc-46692 human mouse 
TGF-β1 Abcam ab64715 human mouse 
Nectin-2 Proteintech  27171-1-AP human rabbit 
PVR Proteintech  27486-1-AP human rabbit 
ITGAV abcam Ab179475 human rabbit 
 
3.1.7 Materials for mass spectrometry (MS) 
50x Protease Inhibitor cocktail  Ref# 11873580001, Merck, Germany 
Triethylammoniumbicarbonate (TEAB) Ref# T7408, Sigma, Germany 
Urea Ref# U1250, Sigma, Germany 
Benzonase HC nuclease Ref# 71206-3, Merck, Germany 
Dithiothreitol (DTT) Ref# A1101, AppliChem, Germany 
2-Chloroacetamide  Ref# 79-07-2, Merck, Germany 
Trypsin   Ref# 9002-07-2, Serva, Germany 
Lysyl Endopeptidase (Lys-C) Ref# 129-02541, WAKO Chemicals 
GmbH, Germany 
Formic acid Ref# 94318, Honeywell/ Fluka, 
Romania 
Acetonitrile  Ref# 1000291000, Merck, Germany 
Methanol Ref# 83638.32, VWR, Germany 
MS grade water  Ref# 270733, Merck, Germany 
3.1.8 Materials for flow cytometry 
3.1.8.1 Reagents for flow cytometry 
TruStain FcX™ (anti-mouse CD16/32)  Cat# 101319, Biolegend, USA 
Cell Staining Buffer  Cat# 420201, Biolegend, USA 
Human TruStain FcX™ (Fc Receptor 
Blocking Solution) 
Cat# 422301, Biolegend, USA 
Red Cell Lysis Buffer Cat# 158904, Qiagen, Germany 
UltraComp eBeads™ Compensation Cat# 01-2222-42, Invitrogen™, Germany 
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Beads 
Zombie Aqua# Fixable Viability Kit Cat# 423102, Biolegend, USA 
Intracellular Staining Permeabilization 
Wash Buffer (10X) 
Cat# 421001, Biolegend, USA 
Polybead® Carboxylate Microspheres 
4.50μm 
Cat# 17140-5, Polysciences, USA 
Brefeldin A Solution (1,000X) Cat# 420601, Biolegend, USA 
Monensin Solution (1,000X) Cat# 420701, Biolegend, USA 
2-NBDG Cat# 11046-1, Cayman  
3.1.8.2 Antibodies for flow cytometry 
Antibody  Company  Cat# 
FITC anti-mouse CD45 Biolegend  103107 
Alexa Fluor® 700 anti-mouse CD3 Biolegend  100215 
PerCP/Cy5.5 anti-mouse CD19 Biolegend  152405 
PE/Dazzle# 594 anti-mouse NK-1.1 Biolegend  108747 
Brilliant Violet 421# anti-mouse CD335 Biolegend  137611 
APC anti-mouse CD49a Biolegend  142605 
PE/Cy7 anti-mouse CD49b Biolegend  103517 
Brilliant Violet 421™ anti-human CD314 (NKG2D) Biolegend  320821 
FITC anti-human CD45 Biolegend  304005 
APC anti-human CD107a (LAMP-1) Biolegend  328619 
PE/Dazzle™ 594 anti-human TNF-α Biolegend  502945 
PE/Cy7 anti-human IFN-γ Biolegend  506517 
FITC anti-human CD98 Biolegend  315603 
PE anti-human CD71 Biolegend  334105 
APC anti-human MICA/MICB Biolegend  320907 
PE Mouse anti-Smad2 (pS465/pS467)/Smad3 
(pS423/pS425) 
BD 
Bioscience 
562586 
3.1.9 Materials for immunofluorescence (IF) and immunohistochemistry (IHC) 
23 
 
3.1.9.1 Reagents for IF and IHC 
Normal Serum Block  Cat# S3023, Dako, USA 
Fluorescence mounting medium Cat# S3023, Dako, USA 
DAPI Cat# D1306, Invitrogen™, Germany 
Dako EnVision+ System, HRP (AEC), 
For use with mouse primary antibodies   
Cat# K4005, Dako, USA 
Dako EnVision+ System, HRP (AEC), 
For use with rabbit primary antibodies   
Cat# K4009, Dako, USA 
Antibody diluent reagent solution Cat# 005218, Life technologies, USA 
Hydrogen Peroxide 30% Cat# CP26.5, Carl Roth, Germany 
Tissue-Tek O.C.T.TM. Cat# 25608-930, VWR, Germany 
Polysine Adhesion Slides Cat# J2800AMNT, Thermo Scientific™, 
Germany  
3.1.9.2 Buffer systems for antigen retrieval 
Tris/EDTA pH 9.0 10 mM Tris 
144 mM Sodium Chloride 
Adjust pH to 9.0, with HCl 
Citric acid pH 6.0 10 mM Citric acid 
Adjust pH to 6.0, with Sodium Hydroxide 
3.1.10 Materials for ELISA 
TGF beta-1 Human/Mouse Uncoated 
ELISA Kit 
Cat# 88-8350-88, Invitrogen, Germany 
Wash buffer  PBS wash buffer with 0.05% Tween-20 
Reagent diluent  1% BSA in PBS 
Substrate solution  TMB Substrate  
Stop solution  H2SO4 
Streptavidin-HRP   
3.1.11 Animal experiments 
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3.1.11.1 Animals 
C57BL/6 mice, 6-8 weeks, female In vivo Research Facility, CECAD 
Cologne, Germany 
NSG mice, 6-8 weeks, female In vivo Research Facility, CECAD 
Cologne, Germany 
3.1.11.2 Surgical instruments 
Forceps Dosch GmbH, Heidelberg, Germany 
Disposable scalpels Feather Safety Razor Co., Japan 
Scissors, sharp / blunt Dosch GmbH, Heidelberg, Germany 
3.1.11.3 Medicine 
Ketaminhydrochlorid (Ketavet), 100 
mg/mL 
Pfizer Pharmacia GmbH, Germany 
Xylazinhydrochlorid, Xylazin 
(Rompun) 2%, 25 mL 
Bayer Healthcare, Germany 
3.1.11.4 Other materials 
Syringe (1mL, 5 mL, 10 ml)  B Braun, Germany 
Injection needle (26G, 28 G)  B Braun, Germany 
Thread with needle USP 4/0 Seralon®  Serag-Wiessner AG, Naila, Germany 
Rotilabo®-embedding cassettes  Cat# K116.1, Carl Roth, Germany 
Roti®-Histofix 4 % Cat# P087.3, Carl Roth, Germany 
Percoll™ Cat# 17-0891-02, VWR, Germany 
PBS (10X), pH 7.4 Cat# 70011044, Gibco Invitrogen, Germany 
3.1.11.5 Percoll solution for intrahepatic lymphocytes isolation 
100% Percoll 10X PBS Percoll 
1 mouse 2.25 mL            20.25 mL 
70% Percoll 100% Percoll RPMI 
1 mouse 10.95 mL          4.7 mL 
45% Percoll 100% Percoll RPMI 
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1 mouse 2.8 mL        3.45 mL 
3.1.12 Chemicals 
Albumin Fraction V Cat# 8076.2, Carl Roth, Germany 
Tris Cat# 9127.2, Carl Roth, Germany 
Glycine Cat# 1313400914, AppliChem, Germany 
SDS Cat# A72495000, AppliChem, Germany 
Methanol Cat# 4627.5, Carl Roth, Germany 
Sodium Chloride Cat# 3957.2, Carl Roth, Germany 
Tween 20 Cat# 9127.2, Carl Roth, Germany 
Xylene Cat# 371.5000, Th. Geyer, Germany 
99% 2-Propanol Cat# 9866.5, Carl Roth, Germany 
96% ethanol Cat# 22065000, Th. Geyer, Germany 
EDTA Cat# E-5134, Merck, Germany 
Citric acid monohydrate  Cat# 100244.0500, Merck, Germany 
3.1.13 Technical equipment 
Biological Safety Cabinets Class II Herasafe KS, Thermo Scientific™, Germany 
 NU-440-400E, NUAIRE, USA 
Air-displacement pipettes  Eppendorf, Germany 
CO2- incubators  Heracell 150i, Thermo Scientific™, 
Germany  
MCO-230AICUV-PE, Panasonic, Japan 
Centrifuges Megafuge 1.0R, Heraeus, Germany 
Megafuge 40R, Heraeus, Germany 
Heraeus™ Fresco™ 17 Microcentrifuge, 
Thermo Scientific™, Germany 
Phase Contrast Microscope DFC450C, Leica, Germany 
Automated Cell Counter Countess II, Invitrogen, USA 
Vortex Lab dancer, VWR, Germany 
Refrigerator 4°C Liebherr, Germany 
Freezer -20°C Bosch, Germany 
Freezer -80°C Sanyo, Japan 
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Freezer -150°C Sanyo, Japan 
Cell freezing container Cell Camper Mini-12, neoLab, Germany 
Water bath Störk-Tronic, Germany 
Ultracentrifuge Optima™ L-90K, Beckman Coulter, USA 
Rotor for Heraeus Megafuge 40R HIGHConic SN999, Thermo Scientific™, 
Germany 
Plate Reader FLUOstar Omega, BMG Labtech, Germany 
Mini-PROTEAN® System Bio-Rad, USA 
Trans-Blot® Turbo™ Transfer System Bio-Rad, USA 
INTAS ECL CHEMOSTAR Intas Science Imaging, Germany 
Microtome Techno-Med GmbH, Germany 
Cryostat Thermo Scientific™, Germany 
PT-Module Cat# A80400011, Thermo Scientific™, 
Germany 
Fluorescent Cell Imager  InCellis, Bertin, France 
Thermocycler Tpersonal, Biometra, Germany 
Thermomixer ThermoMixer C, Eppendorf, Germany 
Spectral Analyzer NanoDrop One, Thermo Scientific™, 
Germany 
Real time PCR QuantStudio 7 flex, Applied Biosystems, 
USA 
Spectrometer Direct Detect®, Merck, Germany 
Mass Spectrometer QExactive Plus/ Easy nLC 1200, Thermo 
Scientific™, Germany  
3.1.14 Consumables 
15 mL centrifuge tubes Sarstedt, Germany 
50 mL centrifuge tubes Sarstedt, Germany 
6, 12, 24 and 96-well cell culture plates Sarstedt, Germany 
Serological pipettes 5mL Sarstedt, Germany 
Serological pipettes 10mL Sarstedt, Germany 
Serological pipettes 25mL Sarstedt, Germany 
Pipette tips 10µL Sarstedt, Germany 
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Pipette tips 200µL Sarstedt, Germany 
Pipette tips 1000µL Sarstedt, Germany 
Tissue culture flask T-25 Sarstedt, Germany 
Tissue culture flask T-75  Sarstedt, Germany 
Tissue culture flask T-150 Sarstedt, Germany 
Cryotubes 1.8 mL Sarstedt, Germany 
Sterile reaction tube Sarstedt, Germany 
Cell counting slide Cat# 734-2676, VWR, Germany 
Ultra-Low Attachment 6-Well Plate Cat# CLS3471, Corning, USA,  
Cell strainer, 40 µm pore size, blue Cat# 734-2760, VWR, Germany 
Cell strainer, 70 µm pore size, blue Cat# 734-2761, VWR, Germany 
3.1.15 Software 
Acrobat Reader DC Professional Adobe Systems Inc., USA 
Microsoft Office 365 (Word, Excel, 
PowerPoint) 
Microsoft Corporation, USA 
ImageJ National Institutes of Health 
Graphpad Prism 8 GraphPad Software, Inc., USA 
EndNote X7 Thomson Reuter, CA, USA 
FlowJo software Treestar Inc., Ashland, USA 
Windows 10 Microsoft Corporation, USA 
3.2 Methods  
3.2.1 Cell culture conditions 
All cell lines were cultured in 25, 75 or 175 cm2 flasks and incubated at 37 °C in a 
humidified incubator with 5% CO2. The culture medium was replaced every 2-3 days. 
Pancreatic cancer cells were passaged with 0.05% Trypsin-EDTA when 80-90% 
confluency was reached. NK-92 cells were cultured in suspension at 0.2-0.6 × 106 
cells/mL. Saturated NK cell culture was passaged 1:2 every 2-3 days. 
3.2.2 Determination of cell number and storage of cells  
The cell number was determined using Countess II Automated Cell Counter 
(Invitrogen). Briefly, 10 µL of cells and 10 µL of trypan blue solution were mixed 
28 
 
thoroughly. Then 10 µL of mixture were pipetted into a dispensable countess chamber 
slide. The slide was inserted into Countess II Automated Cell Counter. The 
concentration of cells was obtained directly from the display. Usually, 1 to 4 million 
cells were centrifuged at 350 g for 5 min. The supernatant was discarded and the pellet 
was resuspended in 1 mL of cryopreservation medium. The tubes were put into a cell 
freezing container (neoLab) and then kept in the -80°C freezer overnight. Next day, the 
tubes were transferred into the -150°C freezer for storage.  
3.2.3 Recultivation of cells  
The appropriate medium was put into a new cell culture flask. The cryopreservation 
tube was taken out from the -150°C freezer. Then the tube was immediately transferred 
into the 37°C water bath and thawed for 1-2 min. After complete thawing, the tube was 
taken out and centrifuged at 350 g for 5 min. After centrifugation, the supernatant was 
discarded. The pellet was resuspended in 1 mL of culture medium and transferred into 
the cell culture flask. 
3.2.4 Establishment of orthotopic PDAC mouse models 
Animal experiments were conducted according to protocols approved by the 
responsible national and local authority (81-02.04.2018.A139, LANUV NRW, 
approved on 20th September 2018). All mice were housed under pathogen-free 
conditions with unrestricted diet and water under a 12:12 h light/dark cycle. Female 
C57BL/6 mice, 6 to 8 weeks of age, were used to establish orthotopic pancreatic cancer 
mouse models. After general anesthesia, shaving, disinfection and abdominal cavity 
opening, the spleen was taken out with the pancreas tail. Generally, 1 × 106 Panc02 
cells were injected into the pancreas tail. After injection, the spleen and pancreas were 
put back into the abdominal cavity. The abdominal cavity was then washed with 
physiological saline twice and closed by a two-layer silk suture. The postoperative 
status of mice was monitored every day. 3 weeks after injection, tumor-bearing mice 
were euthanized by cervical dislocation. The liver without macroscopic metastases was 
perfused with 20 mL PBS and collected for intrahepatic lymphocytes isolation (Figure 
3).  
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3.2.5 Isolation of intrahepatic lymphocytes 
Isolation of intrahepatic lymphocytes was carried out by the mechanical method. Firstly, 
using the plunger of the 2-mL syringe, the liver was squeezed through a 40 µM strainer. 
The strainer and the plunger were washed with PBS. The suspension was centrifuged 
at 300 g at room temperature (RT). Secondly, the supernatant was discarded and the 
pellet was resuspended in 45% Percoll solution. Liver cells were then loaded on the 
layer of 70% Percoll solution. The tube was centrifuged at 800 g for 20 min at RT 
without brake. Thirdly, intrahepatic lymphocytes were aspirated from the Percoll 
interface and washed twice with PBS. Cells was resuspended in PBS and counted for 
flow cytometric analysis (Figure 3). 
Figure 3. Establishment of orthotopic PDAC mouse models and isolation of 
intrahepatic lymphocytes. 
3.2.6 Exosomes isolation 
For exosomes preparation from cell culture supernatants, cells with a confluency of 70-
80% were washed with DPBS for 3 times and were cultured in medium supplemented 
with 10% exosomes-free FBS for additional 24 hours. Exosomes were isolated by a 
differential centrifugation and ultracentrifugation method. In brief, supernatants were 
centrifuged at 300 g for 10 min and 2,000 g for 10 min at 4 °C to remove dead cells and 
cell debris. The supernatants were transferred into new tubes and centrifuged at 10,000 
g for 30 min at 4 °C to remove large vesicles. The supernatants were then transferred 
into ultracentrifugation tubes and ultracentrifuged at 100,000 g for 70 min at 4 °C 
(Beckman Coulter, OptimaTM L-90K). After first round of ultracentrifugation, the 
supernanant was discarded. The pellet was resuspended in PBS and ultracentrifuged 
again at 100,000 g for 70 min at 4 °C. Exosomes were resuspended in 100 μL of PBS 
and stored in the -80°C freezer for future use. 
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Serum exosomes were isolated by a precipitation method using ExoQuick (System 
Biosciences) according to the manufacturer’s instructions. In brief, serum samples were 
centrifuged at 3000 g for 15 min at RT to remove remaining blood cells and cell debris. 
After centrifugation, 250 μL of serum was put into a new tube and mixed with 63 μL 
of ExoQuick Exosome Precipitation Solution. The mixture was incubated at 4°C for 30 
min and then centrifuged at 1500 g at 4°C for 30 min. The supernatant was aspirated. 
The tube was centrifuged at 1500 g for additional 5 min to remove the residual 
ExoQuick solution. The pellet was resuspended completely in 100 μL of PBS. Serum 
exosomes were stored in the -80°C freezer for future use. 
3.2.7 Nanoparticle tracking analysis 
The size distribution of pancreatic cancer-derived exosomes was examined by 
nanoparticle tracking analysis (NTA). Briefly, background measurements were 
performed with filtered PBS, which revealed the absence of any kinds of particles. 
Exosomes were diluted 1:1,000 with PBS. After sample loading, five repeated 
measurements were recorded and then analyzed using a Nanosight NS300 with the 
NTA 3.0 software (Malvern Instruments). 
3.2.8 Transmission electron microscopy 
The morphology of pancreatic cancer-derived exosomes was assessed by transmission 
electron microscopy (TEM). In brief, exosomes were put onto formvar-carbon-coated 
electron microscopy grids for 10 min in a wet chamber. After brief blotting the grid 
edge with filter paper, the grids were placed on drops of 2% aqueous uranyl acetate for 
1 min, removed, blotted again, and placed on H2O drops for 1 min, removed, and blotted 
at the edge. After 24 h of air drying, the grids were inspected using a transmission 
electron microscope (Zeiss EM 912 Omega at 100 kV). 
3.2.9 Western blot 
Cells and exosomes were lysed using complete lysis M buffer supplemented with 
phosphatase inhibitor cocktail (Roche). Protein samples were centrifuged at 14,000 g 
for 15 min at 4°C. After centrifugation, the supernatants were transferred into new tubes 
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and stored in the -80°C freezer. Protein concentrations were measured by BCA Protein 
Assay (Thermo Fisher Scientific). Protein Samples were prepared in Pierce™ LDS 
Sample Buffer (Thermo Fisher Scientific), boiled for 10 min at 70°C. 10-15 µg of 
lysates was loaded and run in SDS polyacrylamide gels. Gels were then transferred onto 
PVDF membranes. The membranes were blocked in Blocking Buffer at RT for 1 hour 
and incubated with specific primary antibodies (as detailed in materials 3.1.6.3) at 4°C 
overnight. Blots were washed 3 × 5 min in PBST. Incubation with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibodies were performed at RT 
for 1 hour. Blots were again washed in TBST 3 × 5 min. Proteins were detected via 
chemiluminescence with SuperSignal™ West Pico PLUS Chemiluminescent Substrate 
(Thermo Fisher Scientific) using Intas ChemoStar ECL Imager (Intas Science Imaging). 
3.2.10 Flow cytometry of exosomes 
Pancreatic cancer-derived exosomes were incubated with and polybead carboxylate 
microspheres (Polyscience) in PBS overnight at 4 °C. Samples were blocked with 2% 
BSA in PBS and centrifuged at 350 g for 2 min. The supernatants were discarded. The 
pellet was washed with PBS twice and resuspended in PBS. Exosomes were incubated 
with the anti-CD63 antibody at 4 °C for 20 min in the dark. The samples were analyzed 
by CytoFlex (Beckman Coulter).  
3.2.11 Flow cytometry of cells 
For surface staining, cells were incubated with Human TruStain FcX™ (Biolegend) on 
ice for 10 min. Then conjugated fluorescent antibodies were added and incubated on 
ice for 20 min in the dark. After incubation, cells were washed in PBS twice and then 
analyzed by flow cytometry. For intracellular staining, surface antigen staining was 
performed as above. Afterwards, cells were washed and fixed in fixation buffer 
(Biolegend) for 20 min at RT. Cells were washed and permeabilized with 
permeabilization wash buffer (Biolegend). Cells were incubated with appropriate 
conjugated fluorescent antibodies in the dark for 20 min at RT. After incubation, cells 
were washed with permeabilization wash buffer twice and analyzed by flow cytometry. 
For each sample, 30,000 to 50,000 events were acquired using CytoFlex (Beckman 
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Coulter). Data were analyzed using FlowJo software. 
3.2.12 Mass spectrometry of exosomes 
50 μg of pancreatic cancer-derived exosomes were used for mass spectrometry analyses. 
First, exosomes were denatured using 8 mol/L urea with Protease inhibitor cocktail. 
Samples were centrifuged for 15 min at 17,000g to remove debris. The protein 
concentration was determined using the Direct Detect® Spectrometer. Then 50 μg per 
sample was transferred into a new 1.5 mL tube. Samples were reduced using 5 mM 
DTT at 25 °C for 1 hour and incubated with 40 mM Chloroacetamide in the dark for 30 
min. This was followed by proteolytic digestion with Lysyl Endopeptidase (Lys-C) at 
an enzyme:substrate ratio of 1:75 at 4 °C for 4 hours. The samples were diluted with 50 
mM TEAB to achieve a final concentration of Urea ≤ 2M. A subsequent digestion with 
trypsin at an enzyme:substrate ratio of 1:75 and incubation at 25°C overnight was 
performed. The digestion was terminated with formic acid at a final concentration of 
1%. After digestion, the peptide mixtures were desalted using in-house made StageTip 
per sample (containing 2 layers of SDB-RPS discs). StageTips were equilibrated as 
follows: 20 μL of Methanol, centrifugation at 2,600 rpm for 1 min; 20 μL of 0.1% 
formic acid in 80% Acetonitrile, centrifugation at 2,600 rpm for 1 min; 20 μL of 0.1% 
formic acid in water, centrifugation at 2,600 rpm for 1.5 min; 20 μL of 0.1% formic 
acid in water, centrifugation at 2,600 rpm for 2 min. The samples (acidified with formic 
acid) were centrifuged at full speed for 5 min and then loaded onto the equilibrated 
StageTips. After centrifugation at 2,600 rpm for 5 min, the StageTips were washed 
according to the following protocol: 30 μL of 0.1% formic acid in water, centrifugation 
at 2,600 rpm for 3 min; 30 μL of 0.1% formic acid in 80% Acetonitrile, centrifugation 
at 2,600 rpm for 3 min. The last wash step was performed twice. Finally, the StageTips 
were dried completely with a syringe and kept at 4 °C until LC-MS Analysis. Nano LC-
MS was performed using a gradient for 150 min and analyzed using the MAXQuant 
and Perseus software.  
3.2.13 In vitro exosomes uptake assay 
Pancreatic cancer cells-derived exosomes were isolated as described above. PKH67 
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Fluorescent Cell Linker kits (Merck) was used to label exosomes according to the 
manufacturer’s instruction. In brief, after first round of ultracentrifugation, the 
supernatant was discarded and the pellet of exosomes was resuspended in 750 μL of 
Diluent C. 1 μL of PKH67 dye was dissolved in 250 μL of Diluent C. Exosomes and 
PKH67 dye were mixed gently and incubated at RT for 5 min. 9 ml of PBS with 1% 
BSA was added to bind excess PKH67 dye. The exosomes were ultracentrifuged at 
100,000 g for 70 min at 4 °C and washed twice in PBS by ultracentrifugation. The 
PKH67-labeled exosomes were then resuspended in PBS. NK cells were incubated with 
PKH67-labeled exosomes for 24 h and put on polysine adhesion slides for 30 min at 
37 °C. After fixation and permeabilization, NK cells were stained with DAPI. Uptake 
of PKH67-labeled exosomes by NK cells was visualized by confocal microscopy. 
3.2.14 In vivo distribution of exosomes 
To study the in vivo distribution of pancreatic cancer-derived exosomes, exosomes were 
fluorescently labeled as described above. Animal experiments were conducted 
according to protocols approved by the responsible national and local authority (81-
02.04.2018.A139, LANUV NRW, approved on 20th September 2018). PKH67-labeled 
exosomes were administered into the tail vein of two healthy 4–6-week-old NSG mice. 
One NSG mouse was injected with PBS as a negative control. Twenty four hours after 
injection, mice were euthanized. Organs were dissected and embedded in Tissue-Tek 
O.C.T.TM. Then samples were frozen and stored at −80 °C. For immunofluorescence, 
10 μm of O.C.T.TM tissue cryosections were stained with DAPI. The distribution of 
PKH67-labeled exosomes was analyzed by confocal microscopy. 
3.2.15 In vitro NK cell cytotoxicity assay 
L3.6pl cells (2 × 105) were plated with NK cells (effector:target=5:1)in a 6-well plate. 
All wells contained 100 IU/mL rhIL-2 with 50% of NK cell medium and 50% of L3.6pl 
culture medium. After co-culture for 24 hours, plates were washed with DPBS for three 
times. Adherent cells were harvested and counted for subsequent experiments. 
3.2.16 Sphere formation assay 
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L3.6pl cells were seeded as single cell suspension at a concentration of 2000 cells/well 
in 6-well ultra-low attachment plates (Corning, USA) in tumor sphere formation assay 
medium as described above. After 7 days, spheres were counted under microscopy. 
Spheres were collected for mRNA extraction and flow cytometric analysis. 
3.2.17 RNA isolation, cDNA synthesis and qRT-PCR 
Total RNA was isolated from cultured cells according to the manufacturer’s 
instructions using the RNeasy Mini Kit (QIAGEN). RNA was reverse transcribed 
according to the manufacturer’s protocol using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The synthesized cDNA was then assessed for 
gene expression using the Fast SYBR green master mix (Invitrogen) with QuantStudio 
7 flex (Applied Biosystems). 
3.2.18 Human studies 
All human tissue and blood samples were collected ethically and their research use was 
according to the terms of the informed consents (BIOMASOTA, ID: 13-091, approval 
in May 2016). Human peripheral blood samples were acquired from healthy subjects 
and PDAC patients at University Hospital of Cologne between October 2016 and 
December 2018. All patients with PDAC were pathologically confirmed. Blood was 
obtained and centrifuged at 2,000 rpm for 10 min and 4,000 rpm for 10 min at RT. 
Serum samples were aliquoted and store in the -80°C freezer. Serum exosomes were 
isolated as described above in the “4.2.5 exosomes isolation” part. Exosomal TGF-β1 
levels in serum were determined using TGF beta-1 Human/Mouse Uncoated ELISA 
Kit (eBiosciences) and analyzed with an ELISA microplate reader at 450 nm. 
3.2.19 Statistical analysis 
Differences between two groups were tested by two-tailed Student’s t test. All statistical 
analyses were made using GraphPad Prism 8. Data were considered statistically 
significant when p value was smaller than 0.05.  
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IV. RESULTS 
4.1 Characterization of pancreatic cancer-derived exosomes 
Exosomes were isolated from cell culture supernatants of a highly metastatic pancreatic 
cancer cell line L3.6pl and a PDAC patient derived primary cancer cell line TBO368 
by differential centrifugation and ultracentrifugation to exclude dead cells, large debris, 
and microvesicles (Figure. 4a). In order to examine the morphology and measure the 
size of pancreatic cancer-derived exosomes, we used transmission electron microscopy 
(TEM) and nanoparticle analysis (NTA). The image of TEM showed that pancreatic 
cancer-derived exosomes displayed features of membrane vesicles (Fig. 4b). The result 
of NTA demonstrated that most of pancreatic cancer-derived exosomes had a diameter 
around 110 nm (Fig. 4c). Exosomes were further characterized by their expression of 
CD9, CD63, CD81, ALIX, Flotillin-1, TSG101 and Rab5, which are commonly used 
markers for exosomes (Fig. 4d & e). Intriguingly, we also detected mutant KRAS 
(G12D) in L3.6pl-derived exosomes, which was consistent with that in genomic DNA 
(Fig. 4f). 
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Figure 4. Characterization of pancreatic cancer cell-derived exosomes. a) 
Exosomes were isolated by differential centrifugation and ultracentrifugation. b) The 
representative image of pancreatic cancer-derived exosomes by TEM. Scale bar, 100 
nm. c) The size of pancreatic cancer-derived exosomes was determined by NTA. The 
size range was 136.1 ± 47.3 nm. d) The expression of exosomal markers ALIX, 
Flotillin-1, TSG101, CD9, CD63, CD81and Rab5 for L3.6pl-derived exosomes and 
parental cells was determined by Western blotting. e) The expression of CD63 on 
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L3.6pl-derived exosomes coupled to carboxylatex beads was analyzed by flow 
cytometry. f) Mutant KRAS (G12D) was detected both in both genomic DNA and 
L3.6pl-derived exosomes. 
4.2 Comprehensive proteomic analysis of pancreatic cancer-derived exosomes  
The proteomic profile of pancreatic cancer-derived exosomes was analyzed by mass 
spectrometry. More than 2,600 proteins were detected in both samples. A significant 
overlap was observed in L3.6pl-derived exosomes and TBO368-derived exosomes. 
(Fig. 5a). 88 of the top 100 most frequently identified exosomal proteins, according to 
the Exocarta database (http://www.exocarta.org), were detected in pancreatic cancer-
derived exosomes. The enrichment of exosomal markers verified the purity of 
exosomes (Fig. 5b).  
To investigate the cellular component, molecular function and biological process of 
proteins in pancreatic cancer-derived exosomes, GO analysis was performed using the 
Gene Ontology Resource (http://geneontology.org/). Proteins were categorized 
according to their ontology as determined from their GO annotation terms. Based on 
the cellular component, around 40% of all the identified proteins were annotated to 
extracellular exosomes (Fig. 5c). The molecular function revealed the enrichment of 
proteins related to translation regulator activity (GO:0045182), transcription regulator 
activity (GO:0140110), molecular transducer activity (GO:0060089), binding 
(GO:0005488), structural molecule activity (GO:0005198), molecular function 
regulator (GO:0098772), catalytic activity (GO:0003824), transporter activity 
(GO:0005215) (Fig. 5d). The biologic process revealed the proteins in pancreatic 
cancer-derived exosomes were involved in cellular component organization or 
biogenesis (GO:0071840), cellular process (GO:0009987), biological phase 
(GO:0044848), localization (GO:0051179), reproduction (GO:0000003), biological 
regulation (GO:0065007), response to stimulus (GO:0050896), developmental process 
(GO:0032502), multicellular organismal process (GO:0032501), biological adhesion 
(GO:0022610), metabolic process (GO:0008152), cell proliferation (GO:0008283), 
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immune system process (GO:0002376) (Fig. 5e). 
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Figure 5. Proteomic analysis of pancreatic cancer-derived exosomes. a) Proteomic 
analysis identified 3,139 proteins in L3.6pl-derived exosomes and 2,691 proteins in 
TBO368-derived exosomes. The Venn diagram showed an overlap of 2,406 proteins in 
both samples. b) Heatmap showed enrichment of typical exosomal markers in L3.6pl-
derived exosomes and TBO368-derived exosomes. c) The cellular component of 
proteins in TBO368-derived exosomes and L3.6pl-derived exosomes. d) The molecular 
function of identified proteins in pancreatic cancer-derived exosomes. e) The biological 
process of identified proteins in pancreatic cancer-derived exosomes.  
4.3 Pancreatic cancer-derived exosomes carry adhesion molecules   
To evaluate the role of pancreatic cancer-derived exosomes in the pre-metastatic niche, 
GO analysis revealed abundant cellular adhesion proteins existed in pancreatic cancer-
derived exosomes, particularly the integrins, such as ITGA1, ITGA2, ITGA3, ITGA6, 
ITGAV, ITGB1, ITGB4, ITGB5, ITGB6 and ITGB8(Fig. 6a & b). We detected the 
expression of Integrin alpha V (ITGAV) in L3.6pl-derived exosomes by Western 
blotting (Fig. 6c). To track in vivo distribution of pancreatic cancer-derived exosomes, 
we further injected PKH67-labelled L3.6pl-derived exosomes intravenously into the 
NSG mice. 24 hours after injection, PKH67-labelled exosomes were detected by 
immunofluorescence in the cryosection of mouse liver tissue, which indicated that 
pancreatic cancer-derived exosomes reached the liver (Fig. 6d).  
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Figure 6. Pancreatic cancer-derived exosomes carry adhesion molecules. a) 
Heatmap of adhesion molecules in L3.6pl-derived exosomes and TBO368-derived 
exosomes, exosomal markers CD9, CD63, CD81 as internal references. b) Integrins in 
L3.6pl-derived exosomes and TBO368-derived exosomes. c) Western blot analysis of 
ITGAV in L3.6pl-derived exosomes. d) Analysis of liver injected with PKH67-labeled 
L3.6pl-derived exosomes (green) by confocal microscopy. Nuclei were stained with 
DAPI (blue). 
4.4 Pancreatic cancer-derived exosomes carry immune regulatory factors 
To investigate the role of tumor-derived exosomes in immune regulation, we first 
analyzed the expression pattern of immune regulatory factors in paired PDAC tumor 
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tissues and adjacent non-tumor tissues based on the GSE28735 dataset (n=45). 
Compared to non-tumor tissues (N), a variety of factors like TGF-β1, TGF-β2, HMGB1, 
PVR, Nectin-2, Galectin-9, PD-L1, PD-L2 and MICA/MICB were significantly higher 
in the tumor tissue (T) (Fig. 7a). Interestingly, enrichment of some molecules, including 
TGF-β1, Nectin-2 and PVR, was demonstrated in pancreatic cancer-derived exosomes 
by Western blotting (Fig. 7b). TGFbRI and TGFbRII (TGF-β1 receptors), DNAM-1, 
TIGIT and CD96 (Nectin-2 and PVR receptors) are present on NK cells. These results 
support the hypothesis that pancreatic cancer-derived exosomes potentially modulate 
NK cell function. 
 
Figure 7. Immune regulatory factors in PDAC and pancreatic cancer-derived 
exosomes. a) Relative mRNA expression of representative immune regulatory factors 
in tumor tissues (T) and non-tumor tissues (N) in pancreatic cancer from GSE28735 
dataset, n = 45. b) The expression of Nectin-2, PVR and TGF-β1 was determined by 
Western blotting in L3.6pl-derived exosomes and L3.6pl cells. ns, no significant 
difference, *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001 by Student’s t test. 
4.5 Intrahepatic lymphocytes in hepatic pre-metastatic niche of PDAC 
It is difficult to explore the hepatic pre-metastatic niche in patients with PDAC due to 
lack of specimen. Thus, we established the orthotopic PDAC mouse models by 
injecting Panc02 cells into the pancreas. Intrahepatic lymphocytes were isolated from 
the hepatic pre-metastatic niche, which was examined by microscopy to make sure no 
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evidence of macro-metastasis or micro-metastasis. We found that there was no 
significant difference of the percentage of T cells, B cells or group 1 innate lymphoid 
cells (ILCs) in CD45+ cells between the PDAC-bearing mice and healthy mice (Figure. 
8b). We then analyzed the percentage of NK cells in group 1 ILCs. Surprisingly, a 
significant decrease of the proportion of NK cells in group 1 ILCs was observed in 
PDAC group (Figure. 8c). This result suggested impaired immune surveillance of NK 
cells in the hepatic pre-metastatic niche of PDAC. 
 
Figure 8. Intrahepatic lymphocytes in the hepatic pre-metastatic niche of PDAC. 
a) Flow cytometry gating strategy for T cells, B cells, group 1 ILCs, NK cells and ILC1s. 
T cells: live CD45+ CD3+, B cells: live CD45+ CD3- CD19+, Group 1 ILCs: live CD45+ 
CD3- CD19- NK1.1+ NKp46+, NK cells: live CD45+ CD3- CD19- NK1.1+ NKp46+ 
CD49a- CD49b+, ILC1s: live CD45+ CD3- CD19- NK1.1+ NKp46+ CD49a+ CD49b-. b) 
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The percentage of T cells, B cells and group 1 ILCs in intrahepatic CD45+ cells from 
PDAC-bearing mice and healthy controls. c) The percentage of NK cells in intrahepatic 
group 1 ILCs from PDAC-bearing mice and healthy controls. Data are means ± SD of 
four mice per group. ns, no statistically significant difference, ****P < 0.0001 by 
Student’s t test. 
4.6 Pancreatic cancer-derived exosomes inhibit NK cell function 
Subsequently, we determined whether NK cell could take up pancreatic cancer-derived 
exosomes. To address this issue, L3.6pl-derived exosomes were stained with PKH67 
(green). PKH67-labelled exosomes were incubated with NK cells. After 24 hours, we 
observed PKH67-lablled exosomes were present on the plasma membrane and in the 
cytoplasma of NK cells (Fig. 9a). This result indicated that pancreatic cancer-derived 
exosomes could be incorporated by NK cells, suggesting their potential role in the 
regulation of NK cell function. Thus, we examined the effects of pancreatic cancer-
derived exosomes on NK cell.  
NKG2D is one of the most important activating receptors on NK cells and the 
expression level of NKG2D correlates positively with their anti-tumor ability[104]. We 
co-cultured NK cells with L3.6pl-derived exosomes or PBS for 24 hours. After co-
culture, the expression of NKG2D in NK cells was significantly downregulated (Fig. 
9b). CD107a is a functional marker for NK cells[105]. TNF-α and IFN-γ are two main 
cytokines produced by activated NK cells[106]. To measure the amount of CD107a, 
TNF-α and IFN-γ, NK cells pre-treated with L3.6pl-derived exosomes or PBS were co-
cultured with L3.6pl cells at an effector:target cell ratio of 1:1 for 5 hours. L3.6pl-
derived exosomes resulted in a significant decrease of CD107a, TNF-α and IFN-γ in 
NK cells (Fig. 9c). Nutrient uptake and glucose metabolism are essential for NK cell 
functionality[66]. CD71 (transferrin receptor), CD98 (large neutral amino acid 
transporter), and 2-NBDG incorporation ability are three commonly used metabolic 
parameters in NK cells[107]. We found that L3.6pl-derived exosomes significantly 
reduced the expression of CD71 and CD98 in NK cells. In addition, L3.6pl-derived 
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exosomes impaired the glucose uptake ability of NK cells (Fig. 9d).  
 
Figure 9. Pancreatic cancer-derived exosomes impair NK cell function. a) Analysis 
of pancreatic cancer-derived exosomes uptake by NK cells using confocal microscopy. 
L3.6pl-derived exosomes were stained with PKH67 (green) and incubated with NK 
cells for 24 hours. The nucleus was labeled with DAPI (blue). b) NK cells were treated 
with PBS or L3.6pl-derived exosomes for 24 hours. The percentage of NKG2D positive 
NK cells were analyzed by flow cytometry. c) NK cells pre-treated with PBS or L3.6pl-
derived exosomes were co-cultured with L3.6pl cells at a 1:1 ratio for 5 hours. The MFI 
of CD107a (left), IFN-γ (middle) and TNF-α (right) in NK cells was analyzed by flow 
cytometry. d) NK cells were treated with PBS or L3.6pl-derived exosomes for 24 hours. 
NK cells were then analyzed by flow cytometry to determine the MFI of CD71 (left), 
and CD98 (middle), 2-NBDG incorporation (right). Data are means ± SD of four 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001 by Student’s t test. 
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4.7 Pancreatic cancer-derived exosomes impair NK cell cytotoxicity 
It has been reported NK cells have the capacity to kill CSCs[108]. We next examined 
whether pancreatic cancer-derived exosomes impaired NK cell cytotoxicity against 
pancreatic CSCs. After enrichment of CSCs using sphere formation assay, we found 
higher mRNA expression levels of NKG2D ligands, MICB and ULBP2 in the CSCs 
population (Figure. 10a). Flow cytometric analysis confirmed a higher MICA/MICB 
expression in spheres than that in adherent cells (Figure. 10b). This indicated that NK 
cells might prefer to recognize and eliminated pancreatic CSCs. NK cells were then 
pre-treated withL3.6pl-derived exosomes in the presence of IL-2 (100 U/ml) for 24 
hours. Then we co-cultured L3.6pl cells with untreated or L3.6pl-derived exosomes 
pre-treated NK cells. After 24-hour killing, floating cells were washed away and 
adherent cells were trypsinized for sphere formation assay (Figure. 10c). we found NK 
cells pre-treated with L3.6pl-derived exosomes showed decreased cytotoxicity against 
pancreatic CSCs (Figure. 10d). 
 
Figure 10. Pancreatic cancer-derived exosomes suppress NK cell cytotoxicity 
against CSCs. a) Gene expression of NKG2D ligands in adherent cells and spheres 
using qRT-PCR. Data are normalized to GAPDH and presented as fold change in 
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comparison with genes in adherent cells. b) The MFI of MICA/MICB in adherent cells 
and spheres was determined by flow cytometry. c) Representative images of tumor 
spheres without NK cell killing(left), tumor spheres after untreated NK cell killing 
(middle), and tumor spheres after L3.6pl-derived exosomes pre-treated NK cell killing 
(right). d) The number of tumor spheres without NK cell killing, tumor spheres after 
untreated NK cell killing, and tumor spheres after L3.6pl-derived exosomes pre-treated 
NK cell killing. Data are means ± SD of four experiments. *P < 0.05, **P < 0.01, **** 
P < 0.0001 by Student’s t test. 
4.8 Pancreatic cancer-derived exosomes phosphorylate Smad2/3 in NK cells 
As a major immunosuppressive cytokine, TGF-β1 inhibits the activation and function 
of NK cells through the TGFβ-Smad2/3 signaling pathway[109]. In our experiments, 
we observed that TGF-β1 attenuated the expression of NKG2D, CD107a, IFN-γ, CD71, 
CD98 and 2-NBDG incorporation ability of NK cells (Fig. 11a, b & c). As shown above, 
pancreatic cancer-derived exosomes contained TGF-β1. Therefore, we investigated 
whether pancreatic cancer-derived exosomes could activate the TGFβ-Smad2/3 
signaling pathway in NK cells. After incubation with TGF-β1 or L3.6pl-derived 
exosomes, the phosphorylation level of Smad2/3 in NK cells was significantly elevated. 
However, in the presence of SB-431542 (an inhibitor of TGFβRI), the phosphorylation 
of Smad2/3 was reversed and returned to the original baseline level (Fig. 11d). These 
findings suggest that pancreatic cancer-derived exosomes deliver TGF-β1 to NK cells, 
induce Smad2/3 phosphorylation, and ultimately result in NK cell dysfunction. 
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Figure 11. Pancreatic cancer-derived exosomes inhibit NK cell function through 
the TGFβ-Smad2/3 signalling pathway. a) NK cells were treated with PBS or TGF-
β1 for 24 hours. The percentage of NKG2D positive NK cells were analyzed by flow 
cytometry. b) NK cells pre-treated with PBS or TGF-β1 were co-cultured with L3.6pl 
cells at a 1:1 ratio for 5 hours. The MFI of CD107a (left), IFN-γ (middle) and TNF-α 
(right) in NK cells was analyzed by flow cytometry. c) NK cells were treated with PBS 
or TGF-β1 for 24 hours. NK cells were then analyzed by flow cytometry to determine 
the MFI of CD71 (left), and CD98 (middle), 2-NBDG incorporation (right). d) After 
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co-culture with TGF-β1 or L3.6pl-derived exosomes in the presence or absence of SB-
431542, the phosphorylation level of SMAD2/3 in NK cells was measured by flow 
cytometry. Data are means ± SD of four experiments. *P < 0.05, **P < 0.01, ***P < 
0.001, **** P < 0.0001 by Student’s t test. 
4.9 Increased exosomal TGF-β1 in serum of patients with PDAC 
The clinicopathological characteristics of patients with PDAC are listed in Table 2. The 
mean age of the patients was 66.1 yrs, and they were predominantly male. All the 
patients donated blood at the time point of diagnosis prior to any treatment (n=30). At 
diagnosis, 53.3% of patients presented with a tumor stage T1 and T2, and 46.7% 
presented with T3 or T4. 77.7 % of patients had a positive lymph node status. 3 patients 
had distant metastases (M1). 56.7% of the patients were UICC I or II and 43.3% were 
UICC III or IV. 19 healthy individuals were included in this study as control (n=19). 
TGF-β1 was overexpressed in PDAC (Fig. 12a). The amount of TGF-β1 in serum 
exosomes was determined by ELISA. The concentration of TGF-β1 per gram of 
exosomes was calculated. The level of exosomal TGF-β1 in the patients with pancreatic 
cancer ranged from 0.20 to 0.88 ng/g. In the healthy donors, it ranged from 0.05 to 0.30 
ng/g. Compared to healthy donors, TGF-β1 in serum exosomes was significantly 
elevated in patients with PDAC (P<0.0001) (Fig. 12b).  
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Table 2. The clinicopathological characteristics  
of patients with PDAC 
 
Figure 12. Elevated serum exosomal TGF-β1 in pancreatic cancer patients. a) The 
IHC result showed TGF-β1 overexpression in tumor tissue of PDAC. b) The amount of 
TGF-β1 per gram of serum exosomes in healthy control (n = 19) and PDAC group 
(n = 30).  
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V. DISCUSSION  
Pancreatic ductal adenocarcinoma is one of the most lethal malignancies[1]. Metastasis 
accounts for a majority of cancer-related deaths in PDAC. Recently, the pre-metastatic 
niche has been proposed to elucidate the mechanisms of the organ-specific metastatic 
process in many cancer entities, such as melanoma, lung cancer and pancreatic 
cancer[28, 96, 110]. Over the past few decades, exosomes have attracted wide attention 
in early detection, diagnosis and treatment of cancer. Moreover, as a mediator of 
intercellular communication, exosomes released from tumor cells are found to interact 
with cells in distant organ sites, and finally induce a pre-metastatic niche for future 
metastasis[111]. Despite tremendous advances, the underlying cellular and molecular 
events involved in pre-metastatic niche formation of PDAC have yet to be determined.  
In the present study, tumor-derived exosomes were isolated from two human pancreatic 
cancer cell lines, L3.6pl and TBO368 by differential centrifugation and 
ultracentrifugation to exclude dead cells, large debris, and microvesicles. Then the 
morphology and size distribution of exosomes were examined by TEM and NTA. 
Exosomal markers, including CD9, CD63, CD81, TSG101, Alix, Flotillin-1 and Rab5 
were identified by Western blotting. Comprehensive proteomic analysis is expected to 
elucidate the potential impact of tumor-derived exosomes on pre-metastatic niche 
formation of PDAC. The proteomic profile of mouse PDAC cell line-derived exosomes 
has been analyzed by previous study. Yu Z et al. compared exosomes derived from 
Panc02 and Panc02-H7 cells using proteomic analyses. The differentially expressed 
proteins in Panc02-H7-derived exosomes were thought to enhance tumor growth, 
invasion and metastasis[112]. To the best of our knowledge, it is the first study to 
systematically analyze the protein content in human PDAC-derived exosomes. By mass 
spectrometry, more than 2,600 proteins were detected in both samples. We found that 
about 90% of the protein identified in L3.6pl-derived exosomes overlapped with those 
identified in TBO368-derived exosomes. GO analysis of identified proteins was 
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performed for cellular components, molecular functions and biologic processes. 
GO-based category clustering of the molecular functions of protein contents in 
pancreatic cancer-derived exosomes suggested that there was a significant enrichment 
in localization and biological adhesion, which may facilitate the ability of exosomes to 
adhere to the surfaces of recipient cells, fuse with their membranes, and transfer 
exosomal components into the target cells to modulate their biological functions. The 
mechanisms of organ-specific homing and colonization of cancer cells are enormously 
complex. Cell adhesion to the extracellular matrix (ECM) determines the colonization 
of metastatic sites and facilitates the survival of circulating tumor cells in the new 
environment. Integrins can bind to fibronectin, vitronectin, laminin, and collagen in 
ECM, thereby enhancing tumor cell motility and invasion ability[113, 114]. Y Liu et 
al. reported that after either intravenous injection or intra-tumor injection, lung cancer-
derived exosomes were detected in the lung and induced a lung pre-metastatic niche in 
mouse models[96]. GO analysis revealed that pancreatic cancer-derived exosomes 
exhibited abundant cellular adhesion molecules, especially integrins. Ayuko Hoshino 
et al. found that tumor-derived exosomal integrins determined organotropic metastasis. 
They reported tumor-derived exosomes carrying integrins α6β4 and α6β1 were 
responsible for lung metastasis, while exosomes carrying integrin αvβ5 were associated 
with liver metastasis[98]. Our findings showed that integrin αv and integrin β5 were 
abundant in pancreatic cancer-derived exosomes. After intravenous injection, PKH67-
labeled pancreatic cancer-derived exosomes reached the liver of the NSG mouse. 
Therefore, we proposed that tumor-derived exosomes tended to enter the liver, 
delivered cargos to the recipient cells, and induced a pre-metastatic niche for future 
metastasis in PDAC. 
A key feature of the pre-metastatic niche is immunosuppression[27]. Chen G et al. 
found that exosomal PD-L1 mediated immune evasion and could be used to predict 
efficacy of anti-PD-1 therapy in metastatic melanoma[115]. Chang-Sook Hong et al. 
reported that circulating exosomes containing immunosuppressive factors interfered 
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immune response in acute myeloid leukemia[116]. In our study, GO analysis revealed 
that identified proteins in pancreatic cancer-derived exosomes were involved in 
biological regulation and immune system process. By Western blotting, we found 
pancreatic-cancer derived exosomes displayed a variety of immune regulatory 
molecules, such as TGF-β1, Nectin-2 and PVR. Therefore, we speculated that 
pancreatic cancer-derived exosomes might be involved in the modulation of immune 
cell functions.  
Most PDAC patients with liver metastases lose the opportunity for curative surgery[1]. 
Hence, it’s difficult to collect liver samples from PDAC patients. Therefore, we 
explored the hepatic pre-metastatic niche in orthotopic PDAC mouse models. In mice, 
group 1 ILCs consist of NK cells and type 1 ILCs. The conversion of effector NK cells 
into type 1 ILCs was reported as a mechanism by which tumor cells escaped from 
immune surveillance[117]. Interestingly, we discovered that compared to healthy mice, 
the percentage of NK cells in group 1 ILC1s showed a significant decrease in the 
hepatic pre-metastatic niche of PDAC-bearing mice. Next, we tried to investigate the 
effects of pancreatic cancer-derived exosomes on NK cells. Firstly, we found that 
pancreatic cancer-derived exosomes could be incorporated by NK cells. Nevertheless, 
it was still uncertain whether pancreatic cancer-derived exosomes could mediate 
immune suppression upon co-incubation with NK cells.  
The stress proteins MICA and MICB are commonly expressed by many human cancers 
due to genomic damage[118]. NKG2D is a key activating receptor for NK cell 
cytotoxicity[104]. The binding of MICA/MICB to NKG2D receptors triggers NK cell 
mediated-cytotoxicity and enables them to eliminate cancer cells[119]. Our result 
indicated that the expression of NKG2D on NK cells was significantly downregulated 
by pancreatic cancer-derived exosomes. This result was consistent with previous 
research[120]. After recognition and activation, NK cells synthesize and release 
effective cytokines into the tumor cells. For example, IFN-γ and TNF-α are two 
indispensable cytokines for NK cell cytotoxicity. Neutralization of IFN-γ and TNF-α 
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significantly impaired NK cell activity[106]. We demonstrated that exosomes treatment 
led to less production of IFN-γ and TNF-α in NK cells. In addition, as a functional 
marker for NK cell activity, the expression of CD107a was also significantly 
downregulated. Recently, the importance of cellular metabolism of immune cells has 
gained increasing attention[121]. Enough nutrients and energy are essential for NK 
effector functions[122]. Cong J et al. demonstrated that the tumor could reduce NK cell 
glycolytic capacity, which resulted in reduced cytotoxicity and NK cell dysfunction[67]. 
We found that NK cells exhibited less CD71 and CD98, as well as reduced glucose 
uptake ability after exosomes treatment. Dysregulated metabolism caused by pancreatic 
cancer-derived exosomes affected multiple biological processes in NK cells, such as 
interfered protein synthesis and impaired energy production. Our result was consistent 
with previous studies investigating the effects of tumor-derived exosomes on immune 
cells[115, 123, 124]. Our findings suggested that pancreatic cancer-derived exosomes 
induced a dysfunctional phenotype of NK cells, which ultimately contributed to an 
immunosuppressive microenvironment in the pre-metastatic niche. 
Pancreatic cancer cells with high aldehyde dehydrogenase 1 (ALDH1) expression are 
considered as cancer stem cells (CSCs)[125]. Ames et al. demonstrated that 
ALDH1bright cells had greater surface expression of ligands for the NK activation 
receptor, NKG2D and NK cells preferentially targeted CSCs[108]. Here, we found that 
after enrichment using sphere formation assay, pancreatic CSCs exhibited high 
expression of ligands for NKG2D. However, pancreatic cancer-derived exosomes 
impaired NK cell cytotoxicity against CSCs. CSCs are often thought to be responsible 
for tumor metastasis[126]. The inhibition of NK cell cytotoxicity allowed pancreatic 
CSCs to escape from NK cell immune surveillance and colonize in the target organ. 
TGF-β signaling pathway is involved in the regulation of fibroblast activation, 
epithelial to mesenchymal transition (EMT), angiogenesis and immunosuppression in 
cancer[127-129]. As a key inhibitory cytokine, TGF-β1 plays a dominant role in 
modulating NK cell function[107, 130]. For example, TGF-β1 attenuated NK cell 
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responses by downregulating NKG2D expression in patients with advanced 
cancer[131]. Among various signals delivered by pancreatic cancer-derived exosomes 
to NK cells, TGF-β1 was thought to be a candidate responsible for NK cell dysfunction. 
Our results showed that TGF-β1 impaired NK cell function, including downregulated 
expression of NKG2D, CD107a, CD71 and CD98, decreased production of cytokines, 
such as TNF-α and IFN-γ, as well as reduced glucose uptake ability. Generally speaking, 
activation of TGF-β/Smad2/3 signaling pathway is implicated in NK cell 
dysfunction[109]. We found that either pancreatic cancer-derived exosomes or TGF-β1 
could induce the phosphorylation of Smad2/3 in NK cells. However, the 
phosphorylation level of Smad2/3 returned to the baseline in the presence of SB-431542. 
Therefore, we proposed that pancreatic cancer-derived exosomes inhibited NK cell 
function via the TGFβ1-Smad2/3 pathway. Pancreatic cancer-derived exosomes 
delivered TGF-β1 to the surface of NK cells, binding to the TGFβ receptors 
(TGFβRI/II). Activation of TGFβRI/II by TGF-β1 induced the phosphorylation of 
serine/threonine residues and triggered phosphorylation of Smad2/3. Then 
phosphorylated-Smad2/3 translocated to the nucleus and regulated gene transcription, 
thereby modulating NK cell function[132]. As a TGFβRI inhibitor, SB-431542 exhibits 
cytotoxicity against pancreatic cancer cells in vitro[133]. Further investigations are 
needed to explore its anti-tumor effect in vivo, especially its influence on phenotypic 
and functional diversity of NK cells. 
Without specific symptoms, it is a major challenge to detect PDAC at early stages. 
Exosomes are promising to be developed as a liquid biopsy tool for early detection and 
diagnosis in PDAC[134]. Recently, it’s reported that the levels of exosomal PD-L1 in 
plasma, rather than soluble PD-L1, were associated with disease progression in patients 
with head and neck squamous cell carcinomas (HNSCCs)[135]. In our study, we 
measured the levels of serum exosomal TGF-β1 in PDAC patients. Interestingly, 
compared to healthy donors, serum exosomal TGF-β1 was significantly elevated in 
PDAC group. Therefore, serum exosomal TGF-β1 holds promise to be used as a 
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diagnostic tool for detection of PDAC. 
Apart from TGF-β1, pancreatic cancer-derived exosomes also contained multiple other 
immune regulatory factors, such as PVR and Nectin-2, which could be delivered as 
inhibitory signals to NK cells. Both PVR and Nectin-2 can bind to inhibitory receptors 
on NK cell, including CD96, PVRIG and TIGIT[70]. Therefore, in addition to TGF-β1, 
PVR and Nectin-2 in pancreatic cancer-derived exosomes could also impaired NK cell 
function. It has been demonstrated that PVR/Nectin-2-TIGIT axis is involved in 
attenuated NK cell cytotoxicity[136]. As a checkpoint receptor, blockade of TIGIT 
prevented NK cell dysfunction and elicited NK cell anti-tumor responses in tumor-
bearing mouse models[137]. Immune checkpoint inhibitors targeting CTLA-4, PD-1, 
and PD-L1 have shown clinical benefit for patients with non-small cell lung cancer 
(NSCLC), advanced melanoma and several other cancers[138-140]. However, these 
inhibitors are less effective in patients with PDAC[141]. Our result indicates that TIGIT 
offers a potential immunotherapeutic target in PDAC. 
Nevertheless, a limitation of the present study was that in vivo effects of human 
pancreatic cancer-derived exosomes on NK cells was not investigated. To address this 
issue, humanized patient-derived xenograft mouse models, which can better 
recapitulate tumor heterogeneity and simulate complexity of immune system, serve as 
a better platform for further investigation[142].  
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Figure 13. The role of tumor-derived exosomes in hepatic pre-metastatic niche 
formation of PDAC 
In conclusion, we propose a novel mechanism of immune escape in PDAC. Pancreatic 
cancer can establish a pre-metastatic niche in the liver via tumor-derived exosomes. 
Pancreatic cancer-derived exosomes carrying immunosuppressive cargos mediate NK 
cell dysfunction. Metastatic pancreatic cancer cells evade immune surveillance of NK 
cells and ultimately generate metastases in the liver (Fig. 13). Additionally, serum 
exosomal TGF-β1 may represent a promising non-invasive diagnostic tool in PDAC. 
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VI. SUMMARY  
Here, tumor-derived exosomes were isolated from a highly metastatic pancreatic cancer 
cell line L3.6pl and a PDAC patient derived primary cancer cell line TBO368 to 
investigate the proteomic profile of exosomes. Distant metastases of PDAC tend to 
occur predominantly in liver and lung. We found that adhesion receptors, especially 
integrins like ITGAV and ITGβ5, which are associated with organ-specific metastases 
in PDAC, were enriched in pancreatic cancer-derived exosomes. In addition, these 
exosomes displayed a variety of immune regulatory factors, such as TGF-β1, Nectin-2 
and PVR. Therefore, we co-cultured NK cells with exosomes derived from pancreatic 
cancer cells. The expression of NKG2D, CD107a, TNF-α and INF-γ in NK cells was 
significantly downregulated. NK cells also exhibited reduced expression of CD71 and 
CD98, as well as impaired glucose uptake ability. Additionally, NK cell cytotoxicity 
against pancreatic CSCs was attenuated. Moreover, pancreatic cancer-derived 
exosomes induced the phosphorylation of Smad2/3 in NK cells. Compared to healthy 
donors, serum exosomal TGF-β1 was significantly increased in patients with PDAC. In 
conclusion, our findings suggest that tumor-derived exosomes mediate NK cell 
dysfunction in the pre-metastatic niche of PDAC. 
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VII. ZUSAMMENFASSUNG 
In dieser Arbeit wird gezeigt, dass die Dysfunktion von NK-Zellen (Natural Killer) in 
der prä-metastatischen Nische der Leber beim duktalen Adenokarzinom des Pankreas 
durch tumor-spezifische Exosomen vermittelt wird. Dazu wurden aus einer 
hochmetastatischen Pankreaskarzinom-Zelllinie, L3.6pl, und einer Primärzelllinie aus 
dem Pankreaskarzinom eines Patienten, TBO368, Exosomen isoliert. Mit Hilfe einer 
Proteomanalyse konnte gezeigt werden, dass Adhäsionsrezeptoren, insbesondere 
Integrine wie ITGAV und ITGβ5, die mit organspezifischen Metastasen im 
Pankreaskarzinom assoziiert sind, in den Exosomen angereichert waren. Darüber 
hinaus wiesen diese Exosomen eine Vielzahl von immunregulatorischen Faktoren wie 
TGF-β1, Nectin-2 und PVR auf. Darauffolgend wurden NK-Zellen mit Exosomen, 
welche aus dem Zellkulturüberstand der Zelllinie L3.6pl isoliert wurden, kultiviert. Die 
Expression von NKG2D, CD107a und INF-γ in den NK-Zellen war signifikant 
herunterreguliert. Die NK-Zellen zeigten ebenfalls eine verminderte Expression von 
CD71 und CD98. Zusätzlich führten die Kultivierung mit tumor-spezifischen 
Exosomen zur Phosphorylierung von Smad2/3 in den NK-Zellen. Im Vergleich zu 
gesunden Spendern war das exosomale TGF-β1 im Serum bei Patienten mit 
Pankreaskarzinom signifikant erhöht. Zusammenfassend beschreiben unsere 
Ergebnisse die immunsuppressiven Effekte von tumor-spezifischen Exosomen und 
liefern neue Erkenntnisse zu unserem Verständnis von NK-Zelldysfunktion in der prä-
metastatischen Nische des duktalen Adenokarzinoms des Pankreas. 
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VIII. ABBREVIATION 
2-NBDG, 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose 
ADCC, antibody-dependent cellular cytotoxicity 
ALDH1, aldehyde dehydrogenase 1   
bFGF, basic fibroblast growth factor 
CAFs, cancer associated fibroblasts 
CSCs, cancer stem cells 
CTCs, circulating tumor cells 
DAPI, 4’, 6-Diamidin-2-phenyl-Indol 
DMEM, Dulbecco's modified eagle medium# 
DMEM, Dulbecco's Modified Eagle's Medium 
DMSO, dimethyl sulfoxide 
DNA, desoxyribonucleic acid 
DPBS, Dulbecco's phosphate-buffered saline  
DTCs, disseminated tumor cells 
ECM, extracellular matrix 
EGF, epidermal growth factor 
ELISA, enzyme-linked immunosorbent assay 
EMT, epithelial-mesenchymal transition 
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EVs, extracellular vesicles 
FACS, fluorescence activated cell scan 
FBS, fetal bovine serum 
FC, flow cytometry 
FCS, fetal calf serum 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase 
GO, Gene Ontology 
HGF, hepatocyte growth factor  
HSCs, hepatic stellate cells  
HUVECs, human umbilical vein endothelial cells 
IF, immunofluorescence 
IF, immunofluorescence 
IFN-γ, interferon-gamma 
IHC, immunohistochemistry 
IL-10, interleukin-10  
IL-2, interleukin-2 
IL-6, interleukin-6 (IL-6),  
KCs, Kupffer cells 
MDSCs, myeloid-derived suppressor cells 
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MEM, Minimum Essential Media 
MFI, mean fluorescence intensity 
MICA, MHC class I chain-related protein A 
MICB, MHC class I chain-related protein B 
MMP, matrix metalloproteinase 
MS, mass spectrometry 
MS, mass spectrometry 
NEAA, Non-Essential Amino Acids 
NK cells, natural killer cells 
NKG2D, natural killer group 2D  
NSG, NOD scid gamma mouse 
NTA, nanoparticle tracking analysis 
NTA, nanoparticle tracking analysis 
PDAC, pancreatic ductal adenocarcinoma  
PGE2, prostaglandin E2 
PSCs, pancreatic stellate cells 
PVR, poliovirus receptor 
RPMI, Roswell Park Memorial Institute 
SEER, the Surveillance, Epidemiology, and End Results  
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STAT3, signal transducer and activator of transcription 3 
TBST, Tris Buffered Saline with Tween 20 
TEM, transmission electron microscope 
TGFbRI, TGF beta receptor 1 
TGFbRII, TGF beta receptor 2  
TGF-β1, transforming growth factor beta 1 
TIGIT, T-cell immunoglobulin and ITIM domain 
TME, tumor microenvironement 
TNF-α, tumor necrosis factor-alpha 
Tregs, regulatory T cells 
VEGF, vascular endothelial growth factor 
WB, Western blot 
 
 
 
 
 
63 
 
IX. REFERENCE  
1. Kamisawa T, Wood LD, Itoi T, Takaori K: Pancreatic cancer. Lancet 2016, 
388(10039):73-85. 
2. Kommalapati A, Tella SH, Goyal G: Contemporary Management of Localized 
Resectable Pancreatic Cancer. 2018, 10(1). 
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin 
SA, Ma WW, Saleh MN et al: Increased survival in pancreatic cancer with nab-
paclitaxel plus gemcitabine. The New England journal of medicine 2013, 
369(18):1691-1703. 
4. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, 
Scheithauer W, Siena S, Tabernero J, Teixeira L et al: nab-Paclitaxel plus gemcitabine 
for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of 
the National Cancer Institute 2015, 107(2). 
5. Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-
Gillam A, Lacy J, Hosein PJ et al: FOLFIRINOX for locally advanced pancreatic 
cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016, 
17(6):801-810. 
6. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer 
metastasis reviews 1989, 8(2):98-101. 
7. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70. 
8. Klein CA: Cancer. The metastasis cascade. Science (New York, NY) 2008, 
321(5897):1785-1787. 
9. Talmadge JE, Fidler IJ: AACR centennial series: the biology of cancer metastasis: 
historical perspective. Cancer research 2010, 70(14):5649-5669. 
10. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 
144(5):646-674. 
11. Lambert AW, Pattabiraman DR, Weinberg RA: Emerging Biological Principles of 
Metastasis. Cell 2017, 168(4):670-691. 
12. Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organ-specific 
colonization. Nature reviews Cancer 2009, 9(4):274-284. 
13. Pantel K, Speicher MR: The biology of circulating tumor cells. Oncogene 2016, 
35(10):1216-1224. 
14. CTCs May Predict Breast Cancer Recurrence. Cancer discovery 2018, 8(2):131. 
15. Pawlikowska P, Faugeroux V, Oulhen M, Aberlenc A, Tayoun T, Pailler E, Farace F: 
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of 
non-small cell lung cancer (NSCLC) therapies. Journal of thoracic disease 2019, 
11(Suppl 1):S45-s56. 
16. Burz C, Pop VV, Buiga R, Daniel S, Samasca G, Aldea C, Lupan I: Circulating tumor 
cells in clinical research and monitoring patients with colorectal cancer. Oncotarget 
2018, 9(36):24561-24571. 
64 
 
17. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, 
Hughes A, Blackhall F et al: A pilot study to explore circulating tumour cells in 
pancreatic cancer as a novel biomarker. British journal of cancer 2012, 106(3):508-
516. 
18. Kulemann B, Rösch S, Seifert S, Timme S, Bronsert P, Seifert G, Martini V, 
Kuvendjiska J, Glatz T, Hussung S et al: Pancreatic cancer: Circulating Tumor Cells 
and Primary Tumors show Heterogeneous KRAS Mutations. Scientific Reports 2017, 
7(1):4510. 
19. Huang Q, Hu X, He W, Zhao Y, Hao S, Wu Q, Li S, Zhang S, Shi M: Fluid shear stress 
and tumor metastasis. American journal of cancer research 2018, 8(5):763-777. 
20. Dhar M, Lam JN, Walser T, Dubinett SM, Rettig MB, Di Carlo D: Functional profiling 
of circulating tumor cells with an integrated vortex capture and single-cell protease 
activity assay. Proceedings of the National Academy of Sciences 2018, 115(40):9986-
9991. 
21. Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, 
Kaplan RN, Bromberg JF, Kang Y et al: Pre-metastatic niches: organ-specific homes 
for metastases. Nature Reviews Cancer 2017, 17:302. 
22. Sleeman JP: The lymph node pre-metastatic niche. Journal of molecular medicine 
(Berlin, Germany) 2015, 93(11):1173-1184. 
23. Seubert B, Grünwald B, Kobuch J, Cui H, Schelter F, Schaten S, Siveke JT, Lim NH, 
Nagase H, Simonavicius N et al: Tissue inhibitor of metalloproteinases (TIMP)-1 
creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil 
recruitment in mice. Hepatology (Baltimore, Md) 2015, 61(1):238-248. 
24. Wang D, Sun H, Wei J, Cen B, DuBois RN: CXCL1 Is Critical for Premetastatic Niche 
Formation and Metastasis in Colorectal Cancer. Cancer research 2017, 77(13):3655-
3665. 
25. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald 
DD, Jin DK, Shido K, Kerns SA et al: VEGFR1-positive haematopoietic bone marrow 
progenitors initiate the pre-metastatic niche. Nature 2005, 438(7069):820-827. 
26. Bubnov R, Polivka J, Jr., Zubor P, Konieczka K, Golubnitschaja O: "Pre-metastatic 
niches" in breast cancer: are they created by or prior to the tumour onset? "Flammer 
Syndrome" relevance to address the question. The EPMA journal 2017, 8(2):141-157. 
27. Liu Y, Cao X: Characteristics and Significance of the Pre-metastatic Niche. Cancer 
cell 2016, 30(5):668-681. 
28. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, 
Hoshino A, Mark MT, Molina H et al: Pancreatic cancer exosomes initiate pre-
metastatic niche formation in the liver. Nature cell biology 2015, 17(6):816-826. 
29. Knolle P, Lohr H, Treichel U, Dienes HP, Lohse A, Schlaack J, Gerken G: 
Parenchymal and nonparenchymal liver cells and their interaction in the local immune 
response. Zeitschrift fur Gastroenterologie 1995, 33(10):613-620. 
30. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 
134(6):1655-1669. 
65 
 
31. Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Hoyer-
Hansen G, Eefsen RL, Reynolds AR, Brodt P: The multifaceted role of the 
microenvironment in liver metastasis: biology and clinical implications. Cancer 
research 2013, 73(7):2031-2043. 
32. Kang N, Gores GJ, Shah VH: Hepatic stellate cells: partners in crime for liver 
metastases? Hepatology (Baltimore, Md) 2011, 54(2):707-713. 
33. Paschos KA, Majeed AW, Bird NC: Role of Kupffer cells in the outgrowth of 
colorectal cancer liver metastases. Hepatology research : the official journal of the 
Japan Society of Hepatology 2010, 40(1):83-94. 
34. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G: Expression patterns of 
matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal 
cells of rat liver: regulation by TNF-alpha and TGF-beta1. Journal of hepatology 1999, 
30(1):48-60. 
35. Brodt P: Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic 
Niches. Clinical cancer research : an official journal of the American Association for 
Cancer Research 2016, 22(24):5971-5982. 
36. Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham 
K, Gladney WL, Hua X et al: Hepatocytes direct the formation of a pro-metastatic 
niche in the liver. Nature 2019. 
37. Robinson MW, Harmon C, O'Farrelly C: Liver immunology and its role in 
inflammation and homeostasis. Cellular & molecular immunology 2016, 13(3):267-
276. 
38. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from 
immunosurveillance to tumor escape. Nature immunology 2002, 3(11):991-998. 
39. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles 
in cancer suppression and promotion. Science (New York, NY) 2011, 331(6024):1565-
1570. 
40. Mittal D, Gubin MM, Schreiber RD, Smyth MJ: New insights into cancer 
immunoediting and its three component phases — elimination, equilibrium and escape. 
Current opinion in immunology 2014, 27:16-25. 
41. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance 
and immunoediting. Immunity 2004, 21(2):137-148. 
42. Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA: Major 
histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor 
tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-
induced MICA/B expression. BMC Cancer 2011, 11:194. 
43. Peiper M, Sato T, Streichert T, Eisenberger CF, Knoefel WT, Izbicki JR: Cytotoxic T 
lymphocyte mediated recognition of human pancreatic cancer cells. International 
journal of cancer 2002, 99(1):88-92. 
44. Bhatia A, Kumar Y: Cancer-Immune Equilibrium: Questions Unanswered. Cancer 
Microenvironment 2011, 4(2):209-217. 
66 
 
45. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, 
Heeschen C: Distinct populations of cancer stem cells determine tumor growth and 
metastatic activity in human pancreatic cancer. Cell stem cell 2007, 1(3):313-323. 
46. Bruttel VS, Wischhusen J: Cancer stem cell immunology: key to understanding 
tumorigenesis and tumor immune escape? Frontiers in Immunology 2014, 5:360. 
47. Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD: The intersection of 
cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro-
Oncology 2016, 18(2):153-159. 
48. Kleffel S, Schatton T: Tumor dormancy and cancer stem cells: two sides of the same 
coin? Advances in experimental medicine and biology 2013, 734:145-179. 
49. Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: 
immunoselection and immunosubversion. Nature reviews Immunology 2006, 
6(10):715-727. 
50. Corthay A: How do Regulatory T Cells Work? Scandinavian Journal of Immunology 
2009, 70(4):326-336. 
51. Kumar V, Patel S, Tcyganov E, Gabrilovich DI: The Nature of Myeloid-Derived 
Suppressor Cells in the Tumor Microenvironment. Trends in immunology 2016, 
37(3):208-220. 
52. Caligiuri MA: Human natural killer cells. Blood 2008, 112(3):461-469. 
53. Chester C, Fritsch K, Kohrt HE: Natural Killer Cell Immunomodulation: Targeting 
Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer 
Immunotherapy. Frontiers in immunology 2015, 6(601). 
54. Houchins JP, Yabe T, McSherry C, Bach FH: DNA sequence analysis of NKG2, a 
family of related cDNA clones encoding type II integral membrane proteins on human 
natural killer cells. The Journal of experimental medicine 1991, 173(4):1017-1020. 
55. Lanier LL: NKG2D Receptor and Its Ligands in Host Defense. Cancer immunology 
research 2015, 3(6):575-582. 
56. Paul S, Lal G: The Molecular Mechanism of Natural Killer Cells Function and Its 
Importance in Cancer Immunotherapy. Frontiers in immunology 2017, 8:1124. 
57. Topham NJ, Hewitt EW: Natural killer cell cytotoxicity: how do they pull the trigger? 
Immunology 2009, 128(1):7-15. 
58. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM: NK Cell-Mediated Antibody-
Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Frontiers in immunology 
2015, 6:368. 
59. O'Sullivan TE, Sun JC, Lanier LL: Natural Killer Cell Memory. Immunity 2015, 
43(4):634-645. 
60. Gurlevik E, Fleischmann-Mundt B, Brooks J, Demir IE, Steiger K, Ribback S, Yevsa 
T, Woller N, Kloos A, Ostroumov D et al: Administration of Gemcitabine After 
Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response 
Mediated by Natural Killer Cells. Gastroenterology 2016, 151(2):338-350.e337. 
61. Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-
Cunningham J, Sckisel GD, Urayama S et al: NK Cells Preferentially Target Tumor 
67 
 
Cells with a Cancer Stem Cell Phenotype. Journal of immunology (Baltimore, Md : 
1950) 2015, 195(8):4010-4019. 
62. Bi J, Tian Z: NK Cell Exhaustion. Frontiers in immunology 2017, 8:760. 
63. Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, Wang J, Song J, Zheng M, Sun H 
et al: High NKG2A expression contributes to NK cell exhaustion and predicts a poor 
prognosis of patients with liver cancer. Oncoimmunology 2017, 6(1):e1264562. 
64. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, 
Dieu-Nosjean MC, Alifano M, Regnard JF et al: Profound coordinated alterations of 
intratumoral NK cell phenotype and function in lung carcinoma. Cancer research 2011, 
71(16):5412-5422. 
65. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, 
Goncalves A, Andre P, Romagne F, Thibault G et al: Human breast cancer cells 
enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin 
Invest 2011, 121(9):3609-3622. 
66. O’Brien KL, Finlay DK: Immunometabolism and natural killer cell responses. Nature 
Reviews Immunology 2019. 
67. Cong J, Wang X, Zheng X, Wang D, Fu B, Sun R, Tian Z, Wei H: Dysfunction of 
Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer 
Progression. Cell metabolism 2018, 28(2):243-255.e245. 
68. Jewett A, Tseng HC: Tumor induced inactivation of natural killer cell cytotoxic 
function; implication in growth, expansion and differentiation of cancer stem cells. 
Journal of Cancer 2011, 2:443-457. 
69. Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y, Zhang Q, Chen G: Hepatocellular 
carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. 
Cancer letters 2012, 318(2):154-161. 
70. Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L: Control of Metastasis by NK Cells. 
Cancer cell 2017, 32(2):135-154. 
71. Chiossone L, Dumas PY: Natural killer cells and other innate lymphoid cells in cancer. 
2018, 18(11):671-688. 
72. Racanelli V, Rehermann B: The liver as an immunological organ. Hepatology 
(Baltimore, Md) 2006, 43(2 Suppl 1):S54-62. 
73. Tkach M, Thery C: Communication by Extracellular Vesicles: Where We Are and 
Where We Need to Go. Cell 2016, 164(6):1226-1232. 
74. Colombo M, Raposo G, Thery C: Biogenesis, secretion, and intercellular interactions 
of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014, 30:255-
289. 
75. Thery C, Zitvogel L, Amigorena S: Exosomes: composition, biogenesis and function. 
Nature reviews Immunology 2002, 2(8):569-579. 
76. Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal 
E, Cappello F, Carvalho J et al: Biological properties of extracellular vesicles and their 
physiological functions. J Extracell Vesicles 2015, 4:27066. 
68 
 
77. De Toro J, Herschlik L, Waldner C, Mongini C: Emerging roles of exosomes in normal 
and pathological conditions: new insights for diagnosis and therapeutic applications. 
Frontiers in immunology 2015, 6:203. 
78. Jan AT, Malik MA, Rahman S, Yeo HR, Lee EJ, Abdullah TS, Choi I: Perspective 
Insights of Exosomes in Neurodegenerative Diseases: A Critical Appraisal. Frontiers 
in aging neuroscience 2017, 9:317. 
79. Zamani P, Fereydouni N, Butler AE, Navashenaq JG, Sahebkar A: The therapeutic and 
diagnostic role of exosomes in cardiovascular diseases. Trends in cardiovascular 
medicine 2018. 
80. Tan L, Wu H, Liu Y, Zhao M, Li D, Lu Q: Recent advances of exosomes in immune 
modulation and autoimmune diseases. Autoimmunity 2016, 49(6):357-365. 
81. Soung YH, Ford S, Zhang V, Chung J: Exosomes in Cancer Diagnostics. Cancers 2017, 
9(1). 
82. Qin W, Tsukasaki Y, Dasgupta S, Mukhopadhyay N, Ikebe M, Sauter ER: Exosomes 
in Human Breast Milk Promote EMT. Clinical cancer research : an official journal of 
the American Association for Cancer Research 2016, 22(17):4517-4524. 
83. Nair S, Tang KD, Kenny L, Punyadeera C: Salivary exosomes as potential biomarkers 
in cancer. Oral oncology 2018, 84:31-40. 
84. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, 
Mittendorf EA, Weitz J, Rahbari N et al: Glypican-1 identifies cancer exosomes and 
detects early pancreatic cancer. Nature 2015, 523(7559):177-182. 
85. Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar 
T, Katz M, Overman MJ et al: High prevalence of mutant KRAS in circulating 
exosome-derived DNA from early-stage pancreatic cancer patients. Annals of 
oncology : official journal of the European Society for Medical Oncology 2017, 
28(4):741-747. 
86. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D: Engineering 
exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacologica 
Sinica 2017, 38:754. 
87. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R: 
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. 
Nature 2017, 546(7659):498-503. 
88. Munoz-Pinedo C, El Mjiyad N, Ricci JE: Cancer metabolism: current perspectives and 
future directions. Cell death & disease 2012, 3:e248. 
89. Takahashi A, Okada R, Nagao K, Kawamata Y, Hanyu A, Yoshimoto S, Takasugi M, 
Watanabe S, Kanemaki MT, Obuse C et al: Exosomes maintain cellular homeostasis 
by excreting harmful DNA from cells. Nature Communications 2017, 8:15287. 
90. Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D: Pancreatic Ductal 
Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the 
Tumor Microenvironment. Frontiers in immunology 2018, 9:1044. 
91. Masamune A, Yoshida N, Hamada S, Takikawa T, Nabeshima T, Shimosegawa T: 
Exosomes derived from pancreatic cancer cells induce activation and profibrogenic 
69 
 
activities in pancreatic stellate cells. Biochemical and biophysical research 
communications 2018, 495(1):71-77. 
92. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, 
Frankel WL, Bekaii-Saab T et al: Pancreatic cancer-associated stellate cells promote 
differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. 
Cancer research 2013, 73(10):3007-3018. 
93. De Palma M, Biziato D, Petrova TV: Microenvironmental regulation of tumour 
angiogenesis. Nature Reviews Cancer 2017, 17:457. 
94. Chiba M, Kubota S, Sato K, Monzen S: Exosomes released from pancreatic cancer 
cells enhance angiogenic activities via dynamin-dependent endocytosis in endothelial 
cells in vitro. Scientific Reports 2018, 8(1):11972. 
95. Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, Zhou K, Liu X, Ren X, Wang F et al: 
Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by 
inducing vascular permeability and angiogenesis. Nature Communications 2018, 
9(1):5395. 
96. Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, Huang B, Xu X, Zheng J, Cao X: 
Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating 
Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer cell 2016, 30(2):243-256. 
97. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, 
Hoshino A, Mark MT, Molina H et al: Pancreatic cancer exosomes initiate pre-
metastatic niche formation in the liver. Nature cell biology 2015, 17(6):816-826. 
98. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, 
Molina H, Kohsaka S, Di Giannatale A, Ceder S et al: Tumour exosome integrins 
determine organotropic metastasis. Nature 2015, 527(7578):329-335. 
99. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ: In vivo selection and 
characterization of metastatic variants from human pancreatic adenocarcinoma by 
using orthotopic implantation in nude mice. Neoplasia (New York, NY) 1999, 1(1):50-
62. 
100. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Jr., 
Schabel FM, Jr.: Induction and chemotherapeutic response of two transplantable ductal 
adenocarcinomas of the pancreas in C57BL/6 mice. Cancer research 1984, 44(2):717-
726. 
101. Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, 
Yoshimura K, Edil B et al: A preclinical murine model of hepatic metastases. Journal 
of visualized experiments : JoVE 2014(91):51677. 
102. Gong JH, Maki G, Klingemann HG: Characterization of a human cell line (NK-92) 
with phenotypical and functional characteristics of activated natural killer cells. 
Leukemia 1994, 8(4):652-658. 
103. Wilhelm SM, Quiros RM, Xiu X, Guitta M, Klingemann H, Print RA: NK-92 cells 
induce cytotoxicity against pancreatic cancer cell lines. Gastroenterology 2003, 
124(4):A804-A805. 
104. Sheppard S, Ferry A, Guedes J, Guerra N: The Paradoxical Role of NKG2D in Cancer 
Immunity. Frontiers in immunology 2018, 9:1808. 
70 
 
105. Alter G, Malenfant JM, Altfeld M: CD107a as a functional marker for the identification 
of natural killer cell activity. Journal of immunological methods 2004, 294(1-2):15-22. 
106. Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD: Natural killer cell-produced IFN-
gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1. 
Journal of leukocyte biology 2012, 91(2):299-309. 
107. Viel S, Marcais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, Degouve S, Djebali 
S, Sanlaville A, Charrier E et al: TGF-beta inhibits the activation and functions of NK 
cells by repressing the mTOR pathway. Science signaling 2016, 9(415):ra19. 
108. Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-
Cunningham J, Sckisel GD, Urayama S et al: NK Cells Preferentially Target Tumor 
Cells with a Cancer Stem Cell Phenotype. The Journal of Immunology 2015:1500447. 
109. Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, Barese C, Murali V, Wu 
MF, Liu H et al: The TGF-β/SMAD pathway is an important mechanism for NK cell 
immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia 2016, 
30(4):800-811. 
110. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, 
Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C et al: Melanoma 
exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype 
through MET. Nat Med 2012, 18(6):883-891. 
111. Steinbichler TB, Dudas J, Riechelmann H, Skvortsova, II: The role of exosomes in 
cancer metastasis. Semin Cancer Biol 2017, 44:170-181. 
112. Yu Z, Zhao S, Ren L, Wang L, Chen Z, Hoffman RM, Zhou J: Pancreatic cancer-
derived exosomes promote tumor metastasis and liver pre-metastatic niche formation. 
Oncotarget 2017, 8(38):63461-63483. 
113. Hamidi H, Ivaska J: Every step of the way: integrins in cancer progression and 
metastasis. 2018, 18(9):533-548. 
114. Bendas G, Borsig L: Cancer cell adhesion and metastasis: selectins, integrins, and the 
inhibitory potential of heparins. International journal of cell biology 2012, 
2012:676731. 
115. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun 
H et al: Exosomal PD-L1 contributes to immunosuppression and is associated with 
anti-PD-1 response. Nature 2018, 560(7718):382-386. 
116. Hong CS, Sharma P, Yerneni SS, Simms P, Jackson EK, Whiteside TL, Boyiadzis M: 
Circulating exosomes carrying an immunosuppressive cargo interfere with cellular 
immunotherapy in acute myeloid leukemia. Sci Rep 2017, 7(1):14684. 
117. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, 
Straube J, Waddell N, Blake SJ et al: Tumor immunoevasion by the conversion of 
effector NK cells into type 1 innate lymphoid cells. 2017, 18(9):1004-1015. 
118. Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate 
immune system ligands of the NKG2D receptor. Nature 2005, 436(7054):1186-1190. 
119. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK 
cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (New York, 
NY) 1999, 285(5428):727-729. 
71 
 
120. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z: Human Tumor-
Derived Exosomes Down-Modulate NKG2D Expression. The Journal of Immunology 
2008, 180(11):7249-7258. 
121. Buck MD, Sowell RT, Kaech SM, Pearce EL: Metabolic Instruction of Immunity. Cell 
2017, 169(4):570-586. 
122. Gardiner CM, Finlay DK: What Fuels Natural Killers? Metabolism and NK Cell 
Responses. Frontiers in immunology 2017, 8:367. 
123. Berchem G, Noman MZ, Bosseler M, Paggetti J, Baconnais S, Le Cam E, Nanbakhsh 
A, Moussay E, Mami-Chouaib F, Janji B et al: Hypoxic tumor-derived microvesicles 
negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a 
transfer. Oncoimmunology 2016, 5(4):e1062968. 
124. Xia Y, Zhang Q, Zhen Q, Zhao Y, Liu N, Li T, Hao Y, Zhang Y, Luo C, Wu X: 
Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma 
patients through the exosomal pathway. Oncotarget 2017, 8(23):37783-37795. 
125. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, 
Evans DB, Gallick GE: ALDH activity selectively defines an enhanced tumor-
initiating cell population relative to CD133 expression in human pancreatic 
adenocarcinoma. PloS one 2011, 6(6):e20636. 
126. Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS: Cancer stem cells and their 
role in metastasis. Pharmacology & therapeutics 2013, 138(2):285-293. 
127. Massague J: TGFbeta in Cancer. Cell 2008, 134(2):215-230. 
128. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P: The polarization of immune 
cells in the tumour environment by TGFbeta. Nature reviews Immunology 2010, 
10(8):554-567. 
129. Yoshimura A, Muto G: TGF-beta function in immune suppression. Current topics in 
microbiology and immunology 2011, 350:127-147. 
130. Zaiatz-Bittencourt V, Finlay DK: Canonical TGF-beta Signaling Pathway Represses 
Human NK Cell Metabolism. 2018, 200(12):3934-3941. 
131. Lee J-C, Lee K-M, Kim D-W, Heo DS: Elevated TGF-β1 Secretion and Down-
Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients. The 
Journal of Immunology 2004, 172(12):7335-7340. 
132. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β 
family signalling. Nature 2003, 425:577. 
133. Halder SK, Beauchamp RD, Datta PK: A specific inhibitor of TGF-beta receptor kinase, 
SB-431542, as a potent antitumor agent for human cancers. Neoplasia (New York, NY) 
2005, 7(5):509-521. 
134. Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T: Liquid biopsy 
in pancreatic cancer: the beginning of a new era. Oncotarget 2018, 9(42):26900-26933. 
135. Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL: Clinical 
Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 2018, 24(4):896-905. 
72 
 
136. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman 
M, Dassa L, Achdout H et al: The interaction of TIGIT with PVR and PVRL2 inhibits 
human NK cell cytotoxicity. Proceedings of the National Academy of Sciences of the 
United States of America 2009, 106(42):17858-17863. 
137. Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H et 
al: Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits 
potent anti-tumor immunity. Nature immunology 2018, 19(7):723-732. 
138. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, 
Joseph RW, Weber JS et al: Safety and tumor responses with lambrolizumab (anti-PD-
1) in melanoma. The New England journal of medicine 2013, 369(2):134-144. 
139. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, 
Pluzanski A, Vokes EE, Holgado E et al: Nivolumab versus Docetaxel in Advanced 
Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine 
2015, 373(2):123-135. 
140. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes 
EE, Felip E, Holgado E et al: Nivolumab versus Docetaxel in Advanced Nonsquamous 
Non-Small-Cell Lung Cancer. The New England journal of medicine 2015, 
373(17):1627-1639. 
141. Morrison AH, Byrne KT, Vonderheide RH: Immunotherapy and Prevention of 
Pancreatic Cancer. Trends in cancer 2018, 4(6):418-428. 
142. Olson B, Li Y, Lin Y, Liu ET, Patnaik A: Mouse Models for Cancer Immunotherapy 
Research. Cancer discovery 2018, 8(11):1358-1365. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
X. ACKNOWLEDGEMENTS 
I would like to thank my supervisor Prof. Karl-Walter Jauch for giving me the 
opportunity to study in Germany. I won’t forget this experience and it will become a 
special memory in my life. I would also express my sincere gratitude to my co-
supervisor Prof. Christiane J. Bruns. Their great guidance and continuous support 
helped me all the time in my study and research. 
I would also like to express the deepest appreciation to Dr. Yue Zhao for her work 
attitude, patience, immense knowledge, and enthusiasm. This thesis would not have 
been possible without her guidance. In addition, she also gave a lot of support on my 
study and life in Cologne. 
I am deeply grateful to Chinese Scholarship Council to provide the economic support 
and Chinese Consulate Munich for their concern and help. Same thanks to Dr. Dong 
Mei Zhang from the International Office of LMU. They provided me a well-organized 
orientation course and living assistance when I arrived in Munich. 
I would also like to express my deep gratitude to Prof. Margarete Odenthal, Dr. Hinrich 
P. Hansen and Dr. Xiaojie Yu. They gave me a lot of advice when I designed my 
research project. 
I also received generous support from Dr. Hans A Schlößer, Dr. Kerstin Wennhold and 
Martin Thelen. They shared a lot of experience in the field of tumor immunology with 
me. 
I am particularly grateful for the assistance given by Prof. Wolfram Friedrich Neiss and 
Tim van Beers. They helped me a lot with the transmission electron microscopy 
technique. 
I would also like to express my deep gratitude to Prof. Margarete Odenthal, Dr. Hinrich 
P. Hansen and Dr. Xiaojie Yu. They gave me a lot of advice when I designed my 
74 
 
research project. 
I would like to express my gratitude to Dr. rer. nat. Günter Krause and Floyd 
Hassenrück for their kind offer of NK-92 cells and their experience in the field of NK 
cell research. 
I would also like to express my very profound gratitude to the technicians of the 
laboratory, Susanne Neiß, Michaela Heitman, AnkeWienand-Dorweiler and Lisa Raatz. 
Throughout my study, their assistance was so crucial to my research project. They also 
took good care of me in my life.  
Every result described in this thesis was accomplished with the help and support of 
fellow labmates and collaborators, Zhefang Wang, Qu Jiang, Jiahui Li, Dr. Jie Qin and 
Qiye Sun. It was an unforgettable experience to work with them during the last three 
years. 
Special thanks to Dr. Yue Zhao, Dr. Hans A Schlößer and Michael Korenkov for for 
constructive criticism of the manuscript.  
I would like to thank my master thesis supervisor Prof. Li Chen and senior fellow 
apprentice, Dr Qing Bao, Zhiwei Wu, Dr Kaibo Chen, Dr. Dike Shi, Dr Hang Zhang, 
Weidong Zhang, and Chengni Zhan for their advice and encouragement. 
A very special gratitude goes to my friend Robert Gutmann and his family. I will never 
forget the great time we spent together.  
I would also like to thank my friends, Guoyan Chen, Keqin Wang, Hongjia Wu, Hongze 
Li, Tingting Xu, Yinchuan Xu, Tianyu Lin, Ting Zhu, Chundi Miu, Chaonan Bian, 
Jiahao Wang and Shimin Yu. They are always there and would like to share their 
experience with me when I am confused.  
And finally, last but by no means least, I would like to express my sincere gratitude to 
to my parents, Youkun Zhao and Mei Li, my uncle, Zhikun Zhao, who have provided 
75 
 
me through for their endless love and speechless care in my life. I am also grateful to 
my other family members and friends for their uncountable support along the way. 
 
 
 
